pathway	cells	BTO	treatment	effect	time	comment	GSE	norm	GPL
GSE1045a	Estrogen	MDA-MB-231 breast cancer cells	BTO:0000815	treated with estradiol	activating	1 h	2 replicates each, part of timeseries	GSE1045	none	GPL96
GSE1045b	Estrogen	MDA-MB-231 breast cancer cells	BTO:0000815	treated with estradiol	activating	2 h	2 replicates each, part of timeseries	GSE1045	none	GPL96
GSE11467	Estrogen	MCF-7 cells	BTO:0000093	treated with 10 nM estradiol	activating	2 h	3 replicates each	GSE11467	none	GPL96
GSE11567a	Estrogen	SKBR3 cells	BTO:0002419	treated with 1ÂµM estradiol	activating	1 h	3 replicates each, control transfection	GSE11567	normalized	GPL6102
GSE11567b	Estrogen	SKBR3 cells	BTO:0002419	treated with 1o ÂµM hydoxytamoxifen	unknown	1 h	3 replicates each, control transfection	GSE11567	normalized	GPL6102
GSE11791	Estrogen	MCF-7 cells	BTO:0000093	treated with 100 nM estradiol	activating	6 h	3 replicates each	GSE11791	none	GPL570
GSE12261	Estrogen	human smooth muscle cells	BTO:0001260	treated with 3 ÂµM 2-methoxyestradiol	activating	4 h	3 replicates each	GSE12261	none	GPL570
GSE13458	Estrogen	MCF-7 cells	BTO:0000093	treated with estradiol	activating	3 h	3 replicates each, contain luciferase knockdown	GSE13458	log	GPL571
GSE13458a	Estrogen	MCF-7 cells	BTO:0000093	treated with estradiol	activating	3 h	3 replicates each, contain luciferase knockdown	GSE13458	log	GPL570
GSE15717	Estrogen	MCF-7 cells	BTO:0000093	treated with estradiol	activating	4 h	3 replicates each	GSE15717	none	GPL96
GSE18592	Estrogen	MCF-7 ER+ breast cancer cells	BTO:0000093	treated with estrogen	activating	1 h	3 replicates each	GSE18592	none	GPL6244
GSE20081	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with estradiol	activating	6 h	3 replicates each, contain control siRNA	GSE20081	none	GPL570
GSE21618a	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with estradiol	activating	1 h	3 replicates each, different treatments, part of timeseries	GSE21618	none	GPL10371
GSE21618b	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with estradiol	activating	2 h	3 replicates each, different treatments, part of timeseries	GSE21618	none	GPL10371
GSE21618c	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with estradiol	activating	3 h	3 replicates each, different treatments, part of timeseries	GSE21618	none	GPL10371
GSE21618d	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with estradiol	activating	6 h	3 replicates each, different treatments, part of timeseries	GSE21618	none	GPL10371
GSE21618e	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with tamoxifen	unknown	1 h	1 replicate each, different treatments, part of timeseries	GSE21618	none	GPL10371
GSE21618f	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with tamoxifen	unknown	2 h	1 replicate each, different treatments, part of timeseries	GSE21618	none	GPL10371
GSE21618g	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with tamoxifen	unknown	3 h	1 replicate each, different treatments, part of timeseries	GSE21618	none	GPL10371
GSE21618h	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with tamoxifen	unknown	6 h	1 replicate each, different treatments, part of timeseries	GSE21618	none	GPL10371
GSE22012	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with estradiol	activating	1 h	4 replicates each	GSE22012	log	GPL6480
GSE22593a	Estrogen	MDA-MB-231ER+ breast cancer cells	BTO:0000815	treated with estradiol	activating	1 h	2 replicates each, part of timeseries	GSE22593	log	GPL96
GSE22593b	Estrogen	MDA-MB-231ER+ breast cancer cells	BTO:0000815	treated with estradiol	activating	2 h	2 replicates each, part of timeseries	GSE22593	log	GPL96
GSE22593c	Estrogen	MDA-MB-231ER+ breast cancer cells	BTO:0000815	treated with estradiol	activating	4 h	2 replicates each, part of timeseries	GSE22593	log	GPL96
GSE23445	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with estradiol	activating	4 h	3 replicates each	GSE23445	log	GPL6244
GSE23500	Estrogen	human normal breast cells	BTO:0000149	treated with estradiol	activating	6 h	3 replicates each	GSE23500	normalized	GPL6947
GSE23610	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with 0.1ÂµM estradiol	activating	6 h	3 replicates each	GSE23610	none	GPL570
GSE24592	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with 10nM estradiol	activating	4 h	2-3 replicates each, contain control siRNA	GSE24592	none	GPL571
GSE25314a	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with 100nM estrogen	activating	6 h	4 replicates each, different treatments	GSE25314	log	GPL6947
GSE25314b	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with 1 ÂµM tamoxifen	unknown	6 h	4 replicates each, different treatments	GSE25314	log	GPL6947
GSE25315	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with 100nM estrogen	activating	6 h	3 replicates each, contain control siRNA	GSE25315	log	GPL10558
GSE26459a	Estrogen	MCF-7 estrogen sensitive breast cancer cells	BTO:0000093	treated with estrogen	activating	4 h	3 replicates each	GSE26459	none	GPL570
GSE26459b	Estrogen	MCF-7 estrogen resistant breast cancer cells	BTO:0000093	treated with estrogen	activating	4 h	3 replicates each	GSE26459	none	GPL570
GSE26834Est	Estrogen	MCF-7 breast cancer cells	BTO:0000093	treated with estradiol	activating	3 h	2-3 replicates each	GSE26834	log	GPL571
GSE28006	Estrogen	MCF-7 breast cancer cell line	BTO:0000093	treated with estradiol	activating	3 h	2 replicates each, contain siControl RNA	GSE28006	normalized	GPL10558
GSE28645	Estrogen	LY2 breast cancer cell line	BTO:0000356	treated with tamoxifen	inhibiting	2 h	4 replicates each, contain control siRNA, tamoxifen acts as antagonist in breast cell lines	GSE28645	log	GPL570
GSE3013a	Estrogen	endometrial epithelial cells	BTO:0001422	treated with estradiol	activating	3 h	2 replicates each on different platforms, different treatments, different tumor stages	GSE3013	none	GPL91
GSE3013b	Estrogen	endometrial epithelial cells	BTO:0001422	treated with estradiol	activating	3 h	2 replicates each on different platforms, different treatments, different tumor stages	GSE3013	none	GPL8300
GSE3013c	Estrogen	endometrial epithelial cells	BTO:0001422	treated with tamoxifen	unknown	3 h	2 replicates each on different platforms, different treatments, different tumor stages	GSE3013	none	GPL8300
GSE3013d	Estrogen	endometrial epithelial cells	BTO:0001422	treated with tamoxifen	unknown	3 h	2 replicates each on different platforms, different treatments, different tumor stages	GSE3013	none	GPL91
GSE3013f	Estrogen	endometrial epithelial cells	BTO:0001422	treated with estradiol	activating	3 h	2 replicates each on different platforms, different treatments, different tumor stages	GSE3013	none	GPL8300
GSE3013h	Estrogen	endometrial epithelial cells	BTO:0001422	treated with tamoxifen	unknown	3 h	2 replicates each on different platforms, different treatments, different tumor stages	GSE3013	none	GPL91
GSE3013i	Estrogen	endometrial epithelial cells	BTO:0001422	treated with estradiol	activating	3 h	2 replicates each on different platforms, different treatments, different tumor stages	GSE3013	none	GPL8300
GSE3013j	Estrogen	endometrial epithelial cells	BTO:0001422	treated with estradiol	activating	3 h	2 replicates each on different platforms, different treatments, different tumor stages	GSE3013	none	GPL8300
GSE3013k	Estrogen	endometrial epithelial cells	BTO:0001422	treated with tamoxifen	unknown	3 h	2 replicates each on different platforms, different treatments, different tumor stages	GSE3013	none	GPL8300
GSE3013l	Estrogen	endometrial epithelial cells	BTO:0001422	treated with tamoxifen	unknown	3 h	2 replicates each on different platforms, different treatments, different tumor stages	GSE3013	none	GPL8300
GSE30931	Estrogen	MCF-7 breast cancer cell line	BTO:0000093	treated with estrogen	activating	6 h	3 replicates each	GSE30931	log	GPL10558
GSE35287a	Estrogen	endometrial fibroblasts	BTO:0001422	treated with E2	activating	6 h	1 replicate each, 4 donors	GSE35287	normalized	GPL6244
GSE35287b	Estrogen	endometrial fibroblasts	BTO:0001422	treated with E2	activating	6 h	1 replicate each, 4 donors	GSE35287	normalized	GPL6244
GSE35287c	Estrogen	endometrial fibroblasts	BTO:0001422	treated with E2	activating	6 h	1 replicate each, 4 donors	GSE35287	normalized	GPL6244
GSE35287d	Estrogen	endometrial fibroblasts	BTO:0001422	treated with E2	activating	6 h	1 replicate each, 4 donors	GSE35287	normalized	GPL6244
GSE3834a	Estrogen	MCF-7 cells	BTO:0000093	treated with 10 nM estradiol	activating	1 h	2 replicates each, different cell lines, part of timeseries	GSE3834	log	GPL96
GSE3834b	Estrogen	MCF-7 cells	BTO:0000093	treated with 10 nM estradiol	activating	2 h	2 replicates each, different cell lines, part of timeseries	GSE3834	log	GPL96
GSE3834c	Estrogen	MCF-7 cells	BTO:0000093	treated with 10 nM estradiol	activating	4 h	2 replicates each, different cell lines, part of timeseries	GSE3834	log	GPL96
GSE3834d	Estrogen	T47-D cells	BTO:0001248	treated with 10 nM estradiol	activating	1 h	2 replicates each, different cell lines, part of timeseries	GSE3834	log	GPL570
GSE3834e	Estrogen	T47-D cells	BTO:0001248	treated with 10 nM estradiol	activating	2 h	2 replicates each, different cell lines, part of timeseries	GSE3834	log	GPL570
GSE3834f	Estrogen	T47-D cells	BTO:0001248	treated with 10 nM estradiol	activating	4 h	2 replicates each, different cell lines, part of timeseries	GSE3834	log	GPL570
GSE3834g	Estrogen	BT-474 cells	BTO:0001932	treated with 10 nM estradiol	activating	2 h	2 replicates each, different cell lines, part of timeseries	GSE3834	log	GPL570
GSE3834h	Estrogen	BT-474 cells	BTO:0001932	treated with 10 nM estradiol	activating	4 h	2 replicates each, different cell lines, part of timeseries	GSE3834	log	GPL570
GSE5258Est	Estrogen	MCF-7 cells	BTO:0000093	treated with 10 nM estradiol	activating	6 h	1-2 replicates each	GSE5258	none	GPL96
GSE9936a	Estrogen	MCF-7 cells	BTO:0000093	treated with 6 nM estradiol	activating	4 h	3 replicates each, different treatments, contain control vectors	GSE9936	log	GPL96
GSE9936b	Estrogen	MCF-7 cells	BTO:0000093	treated with 6 nM genistein	activating	4 h	3 replicates each, different treatments, contain control vector	GSE9936	log	GPL96
GSE9936c	Estrogen	MCF-7 cells	BTO:0000093	treated with 300 nM genistein	activating	4 h	3 replicates each, different treatments, contain control vector	GSE9936	log	GPL96
GSE21800a	H2O2	4 lymphoid cell lines pooled	BTO:0001586	treated with 9 ÂµM H2O2	activating	4 h	1 replicate each, timerespective control	GSE21800	none	GPL6244
GSE21800b	H2O2	4 lymphoid cell lines pooled	BTO:0001586	treated with 90 ÂµM H2O2	activating	4 h	1 replicate each, timerespective control	GSE21800	none	GPL6244
GSE21800c	H2O2	4 lymphoid cell lines pooled	BTO:0001586	treated with 900 ÂµM H2O2	activating	4 h	1 replicate each, timerespective control	GSE21800	none	GPL6244
GSE22463a	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	3 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463b	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	3 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463c	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	3 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463d	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	3 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463e	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	3 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463f	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	3 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463g	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	3 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463h	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	3 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463i	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	6 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463j	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	6 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463k	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	6 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463l	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	6 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463m	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	6 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463n	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	6 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463o	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	6 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE22463p	H2O2	PBMCs from >50 year old female	BTO:0001025	treated with H2O2	activating	6 h	1 replicate each, timeseries, 8 older individuals	GSE22463	none	GPL6244
GSE5339a	H2O2	ATCC 16Lu ( human lung fibroblasts)	BTO:0000764	H2O2 treatment	activating	1 h	timeseries 1, 4, 12, 24 h	GSE5339	nolog	GPL571
GSE5339b	H2O2	ATCC 16Lu ( human lung fibroblasts)	BTO:0000764	H2O2 treatment	activating	4 h	timeseries 1, 4, 12, 24 h	GSE5339	nolog	GPL571
GSE1056	Hypoxia	Hep3B cells	BTO:0000972	treated with 1% oxygen hypoxia	activating	2 h	2 replicates each	GSE1056	none	GPL91
GSE17188a	Hypoxia	MDA-MB-231 LM2 cells	BTO:0000815	treated with 1% oxygen hypoxia	activating	6 h	2 replicates each, different cell lines	GSE17188	log	GPL6480
GSE17188b	Hypoxia	MDA-MB-231 SCP2 cells	BTO:0000815	treated with 1% oxygen hypoxia	activating	6 h	2 replicates each, different cell lines	GSE17188	log	GPL6480
GSE18494a	Hypoxia	HepG2 cells	BTO:0000599	treated with 0.5% oxygen hypoxia	activating	4 h	3 replicates each, different cell lines	GSE18494	normalized	GPL9419
GSE18494b	Hypoxia	U87 cells	BTO:0002036	treated with 0.5% oxygen hypoxia	activating	4 h	3 replicates each, different cell lines	GSE18494	normalized	GPL9419
GSE18494c	Hypoxia	MB231 cells	BTO:0000815	treated with 0.5% oxygen hypoxia	activating	4 h	3 replicates each, different cell lines	GSE18494	normalized	GPL9419
GSE19123	Hypoxia	MCF-7 cells	BTO:0000093	treated with 1% oxygen hypoxia	activating	4 h	5 replicates each	GSE19123	normalized	GPL570
GSE25452	Hypoxia	HEK293 cells	BTO:0000007	treated with 1% oxygen hypoxia	activating	2 h	2 replicates each, contain control vector	GSE25452	normalized	GPL5188
GSE27813	Hypoxia	MCF-7 cells	BTO:0000093	treated with 1% oxygen hypoxia	activating	6 h	2 replicates each, contain control shRNA	GSE27813	normalized	GPL10558
GSE28603a	Hypoxia	SGBS adipocytes	BTO:0000443	treated with 1% oxygen hypoxia	activating	3 h	3 replicates each, part of timeseries	GSE28603	none	GPL570
GSE28603b	Hypoxia	SGBS adipocytes	BTO:0000443	treated with 1% oxygen hypoxia	activating	6 h	3 replicates each, part of timeseries	GSE28603	none	GPL570
GSE33521	Hypoxia	HeLa cells	BTO:0000567	treated with 1% oxygen hypoxia	activating	6 h	2 replicates each	GSE33521	normalized	GPL6480
GSE5258	Hypoxia	MCF7 cells	BTO:0000093	treated with 0.1mM cobalt chloride	activating	6 h	3 replicates each, cobald cloride induces HIF1	GSE5258	none	GPL96
GSE22325	IL1	HUVECs	BTO:0001949	treated with 100U IL-1b	activating	4 h	1 replicate each	GSE22325	log	GPL570
GSE32390a	IL1	skin fibroblasts	BTO:0001255	treated with 20 ng/ml IL-1b	activating	4 h	1 replicate each, 3 donors	GSE32390	normalized	GPL10558
GSE32390b	IL1	skin fibroblasts	BTO:0001255	treated with 20 ng/ml IL-1b	activating	4 h	1 replicate each, 3 donors	GSE32390	normalized	GPL10558
GSE32390c	IL1	skin fibroblasts	BTO:0001255	treated with 20 ng/ml IL-1b	activating	4 h	1 replicate each, 3 donors	GSE32390	normalized	GPL10558
GSE8515IL1	IL1	Human monocyte-derived macrophages	BTO:0000801	with IL-1 (15 ng/ml)	activating	4 h	5 replicates each	GSE8515	log	GPL96
GSE9120a	IL1	Cultured epidermal keratinocytes	BTO:0000667	treated with 25 ng/ml human recombinant IL-1	activating	1 h	NA	GSE9120	log	GPL571
GSE9120b	IL1	Cultured epidermal keratinocytes	BTO:0000667	treated with 25 ng/ml human recombinant IL-1	activating	4 h	NA	GSE9120	log	GPL571
GSE973a	IL1	HUVEC	BTO:0001949	treated with 100 U/ml human IL-1	activating	0.5 h	timeseries 3 timepoints	GSE973	log	GPL96
GSE973b	IL1	HUVEC	BTO:0001949	treated with 100 U/ml human IL-1	activating	1 h	timeseries 3 timepoints	GSE973	log	GPL96
GSE973c	IL1	HUVEC	BTO:0001949	treated with 100 U/ml human IL-1	activating	2.5 h	timeseries 3 timepoints	GSE973	log	GPL96
GSE21727	Insulin	trabecular bone cells	BTO:0001700	treated with IGF-1	activating	2 h	3 replicates each	GSE21727	normalized	GPL6104
GSE21989a	Insulin	HUVECs	BTO:0001949	treated with Insulin	activating	0.66 h	1 replicate each, part of timeseries	GSE21989	normalized	GPL570
GSE21989b	Insulin	HUVECs	BTO:0001949	treated with Insulin	activating	1.66 h	1 replicate each, part of timeseries	GSE21989	normalized	GPL570
GSE21989c	Insulin	HUVECs	BTO:0001949	treated with Insulin	activating	3.33 h	1 replicate each, part of timeseries	GSE21989	normalized	GPL570
GSE21989d	Insulin	HUVECs	BTO:0001949	treated with Insulin	activating	5.66 h	1 replicate each, part of timeseries	GSE21989	normalized	GPL570
GSE24422a	Insulin	hMSC adipocytes, mixed fraction	BTO:0003298	treated with 20 nM Insulin	activating	5 h	2 replicates each, different fractions of cells	GSE24422	log	GPL570
GSE24422b	Insulin	hMSC adipocytes, adipocyte fraction	BTO:0003298	treated with 20 nM Insulin	activating	5 h	2 replicates each, different fractions of cells	GSE24422	log	GPL570
GSE24422c	Insulin	hMSC adipocytes, stromal fraction	BTO:0003298	treated with 20 nM Insulin	activating	5 h	2 replicates each, different fractions of cells	GSE24422	log	GPL570
GSE26834	Insulin	MCF-7 breast cancer cells	BTO:0000093	treated with IGF-1	activating	3 h	2 replicates for control, 3 replicates for treatment	GSE26834	log	GPL571
GSE30524	Insulin	RPMI 8266 cells	BTO:0000726	treated with 0.375ÂµM picropodophyllin, IGF1R inhibitor	inhibiting	6 h	1 replicate each	GSE30524	log	GPL570
GSE9105a	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105b	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105c	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105d	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105e	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105f	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105g	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105h	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105i	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105j	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105k	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105l	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105m	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105n	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105o	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105p	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105q	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105r	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105s	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105t	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105u	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105v	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105w	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	0.5 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE9105x	Insulin	primary muscle cells	BTO:0001563	treated with euglycemic hyperinsulinemic clamp	activating	4 h	1 replicate each, part of timeseries, 12 donors	GSE9105	normalized	GPL96
GSE10685	JAK-STAT	skeletal muscle biopsies	BTO:0001103	patients treated with IL-6 infusion	activating	3 h	3 donors	GSE10685	nolog	GPL570
GSE12664	JAK-STAT	A549 cells	BTO:0000018	treated with IFNb	activating	6 h	3 replicates	GSE12664	log	GPL6480
GSE1432a	JAK-STAT	primary human microglial cells Y20	BTO:0000078	treated with IFN-gamma (respective timecontrol)	activating	1 h	NA	GSE1432	log	GPL96
GSE1432b	JAK-STAT	primary human microglial cells B18	BTO:0000078	treated with IFN-gamma (respective timecontrol)	activating	1 h	NA	GSE1432	log	GPL96
GSE1432c	JAK-STAT	primary human microglial cells W	BTO:0000078	treated with IFN-gamma (respective timecontrol)	activating	1 h	NA	GSE1432	log	GPL96
GSE1432d	JAK-STAT	primary human microglial cells O	BTO:0000078	treated with IFN-gamma (respective timecontrol)	activating	1 h	NA	GSE1432	log	GPL96
GSE14632a	JAK-STAT	HepG2 hepatocarcinoma cell line	BTO:0000599	treated with 20ng/ml IL-6	activating	1 h	2 replicates, part of timeseries, 4h serum starvation before treatment	GSE14632	log	GPL6104
GSE14632b	JAK-STAT	HepG2 hepatocarcinoma cell line	BTO:0000599	treated with 20ng/ml IL-6	activating	2 h	2 replicates, part of timeseries, 4h serum starvation before treatment	GSE14632	log	GPL6104
GSE14632c	JAK-STAT	HepG2 hepatocarcinoma cell line	BTO:0000599	treated with 20ng/ml IL-6	activating	4 h	2 replicates, part of timeseries, 4h serum starvation before treatment	GSE14632	log	GPL6104
GSE15743a	JAK-STAT	primary NK cells	BTO:0000914	treated with 1 ng/ml IFNa-2b	activating	6 h	1 replicate, 2 concentrations	GSE15743	none	GPL570
GSE15743b	JAK-STAT	primary NK cells	BTO:0000914	treated with 100 ng/ml IFNa-2b	activating	6 h	1 replicate, 2 concentrations	GSE15743	none	GPL570
GSE16251a	JAK-STAT	primary PBMCs	BTO:0001025	treated with IFNa	activating	4 h	1 replicate, timerespective control, part of time	GSE16251	log	GPL8601
GSE16251b	JAK-STAT	primary PBMCs	BTO:0001025	treated with IFNa	activating	0.5 h	1 replicate, timerespective control, part of time	GSE16251	log	GPL8601
GSE16251c	JAK-STAT	primary PBMCs	BTO:0001025	treated with IIL12	activating	0.5 h	1 replicate, timerespective control, part of time	GSE16251	log	GPL8601
GSE16251d	JAK-STAT	primary PBMCs	BTO:0001025	treated with IIL12	activating	1 h	1 replicate, timerespective control, part of time	GSE16251	log	GPL8601
GSE16251e	JAK-STAT	primary PBMCs	BTO:0001025	treated with IIL12	activating	4 h	1 replicate, timerespective control, part of time	GSE16251	log	GPL8601
GSE16252a	JAK-STAT	primary PBMCs	BTO:0001025	treated with 0.6 pM IFNg	activating	0.5 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16252b	JAK-STAT	primary PBMCs	BTO:0001025	treated with 0.6 pM IFNg	activating	1 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16252c	JAK-STAT	primary PBMCs	BTO:0001025	treated with 0.6 pM IFNg	activating	2 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16252d	JAK-STAT	primary PBMCs	BTO:0001025	treated with 0.6 pM IFNg	activating	4 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16252e	JAK-STAT	primary PBMCs	BTO:0001025	treated with 60 pM IFNg	activating	0.5 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16252f	JAK-STAT	primary PBMCs	BTO:0001025	treated with 60 pM IFNg	activating	1 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16252g	JAK-STAT	primary PBMCs	BTO:0001025	treated with 60 pM IFNg	activating	2 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16252h	JAK-STAT	primary PBMCs	BTO:0001025	treated with 60 pM IFNg	activating	4 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16252i	JAK-STAT	primary PBMCs	BTO:0001025	treated with 0.006 pM IFNg	activating	0.5 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16252j	JAK-STAT	primary PBMCs	BTO:0001025	treated with 0.006 pM IFNg	activating	1 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16252k	JAK-STAT	primary PBMCs	BTO:0001025	treated with 0.006 pM IFNg	activating	2 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16252l	JAK-STAT	primary PBMCs	BTO:0001025	treated with 0.006 pM IFNg	activating	4 h	1 replicate, timerespective control, part of timeand concentration series	GSE16252	log	GPL8601
GSE16253a	JAK-STAT	primary monocytes	BTO:0000876	treated with 0.6 pM IFNg	activating	0.5 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253b	JAK-STAT	primary monocytes	BTO:0000876	treated with 0.6 pM IFNg	activating	4 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253c	JAK-STAT	primary monocytes	BTO:0000876	treated with 0.6 pM IFNg	activating	1 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253d	JAK-STAT	primary B cells	BTO:0000776	treated with 0.6 pM IFNg	activating	0.5 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253e	JAK-STAT	primary B cells	BTO:0000776	treated with 0.6 pM IFNg	activating	1 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253f	JAK-STAT	primary B cells	BTO:0000776	treated with 0.6 pM IFNg	activating	4 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253g	JAK-STAT	primary CD4+ T cells	BTO:0002417	treated with 0.6 pM IFNg	activating	0.5 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253h	JAK-STAT	primary CD4+ T cells	BTO:0002417	treated with 0.6 pM IFNg	activating	1 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253j	JAK-STAT	primary NK cells	BTO:0000914	treated with 0.6 pM IFNg	activating	4 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253k	JAK-STAT	primary NK cells	BTO:0000914	treated with 0.6 pM IFNg	activating	1 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253l	JAK-STAT	primary NK cells	BTO:0000914	treated with 0.6 pM IFNg	activating	0.5 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253m	JAK-STAT	primary CD8+ T cells	BTO:0000782	treated with 0.6 pM IFNg	activating	0.5 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253n	JAK-STAT	primary CD8+ T cells	BTO:0000782	treated with 0.6 pM IFNg	activating	1 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16253o	JAK-STAT	primary CD8+ T cells	BTO:0000782	treated with 0.6 pM IFNg	activating	4 h	1 replicate, timerespective control, part of timeseries, different cell lines	GSE16253	log	GPL8601
GSE16385	JAK-STAT	primary macrophage	BTO:0000801	treated with IL-4	activating	4 h	1 replicate, respective timecontrol	GSE16385	normalized	GPL570
GSE16450a	JAK-STAT	immature BE(2)-C neuroblastoma cell line	BTO:0000932	treated with IFNa-A/D	activating	6 h	3 replicates	GSE16450	none	GPL570
GSE16450b	JAK-STAT	mature BE(2)-C neuroblastoma cell line	BTO:0000932	treated with IFNa-A/D	activating	6 h	3 replicates	GSE16450	none	GPL570
GSE16755	JAK-STAT	macrophages	BTO:0000801	treated with IFNa	activating	unknown	3 replicates	GSE16755	none	GPL570
GSE19082a	JAK-STAT	HMEC (human microvascular endothelial cells)	BTO:0002178	treated with IFN-gamma 1 ng/ml (respective timecontrol)	activating	3 h	4 replicates each two different treatments	GSE19082	nolog	GPL6104
GSE19082b	JAK-STAT	HMEC (human microvascular endothelial cells)	BTO:0002178	treated with IL-6 50 U/ml  (respective timecontrol)	activating	1 h	4 replicates each, two different treatments	GSE19082	nolog	GPL6104
GSE1925a	JAK-STAT	primary human CD14+ macrophages Pool1	BTO:0000801	treated with IFN-gamma	activating	3 h	NA	GSE1925	log	GPL8300
GSE1925b	JAK-STAT	primary human CD14+ macrophages Pool2	BTO:0000801	treated with IFN-gamma	activating	3 h	NA	GSE1925	log	GPL8300
GSE1925c	JAK-STAT	primary human CD14+ macrophages Pool3	BTO:0000801	treated with IFN-gamma	activating	3 h	NA	GSE1925	log	GPL8300
GSE20198a	JAK-STAT	activated cord blood CD4+ T cells	BTO:0004053	treated with IFNa	activating	2 h	1 replicate, part of timeseries	GSE20198	none	GPL96
GSE20198b	JAK-STAT	activated cord blood CD4+ T cells	BTO:0004053	treated with IFNa	activating	6 h	1 replicate, part of timeseries	GSE20198	none	GPL96
GSE20272a	JAK-STAT	SKOV-3 ovarian cancer cell line	BTO:0000948	treated with IL-6	activating	1 h	1 replicate, 2 different cell lines	GSE20272	none	GPL570
GSE20272b	JAK-STAT	Caov-3 ovarian cancer cell line	BTO:0000814	treated with IL-6	activating	1 h	1 replicate, 2 different cell lines	GSE20272	none	GPL570
GSE21760a	JAK-STAT	HeLa cells	BTO:0000567	treated with IFNg	activating	2 h	1 replicate, part of timeseries	GSE21760	normalized	GPL570
GSE21760b	JAK-STAT	HeLa cells	BTO:0000567	treated with IFNg	activating	4 h	1 replicate, part of timeseries	GSE21760	normalized	GPL570
GSE21760c	JAK-STAT	HeLa cells	BTO:0000567	treated with IFNg	activating	6 h	1 replicate, part of timeseries	GSE21760	normalized	GPL570
GSE22325a	JAK-STAT	HUVECs	BTO:0001949	treated with 100 U/ml IL-3	activating	4 h	1 replicate each, timeresolved control	GSE22325	log	GPL570
GSE22325b	JAK-STAT	HUVECs	BTO:0001949	treated with 100 U/ml IL-6	activating	4 h	1 replicate each, timeresolved control	GSE22325	log	GPL570
GSE23307a	JAK-STAT	primary B cells	BTO:0000776	treated with IFN-b	activating	3 h	1 replicate each, respective timecontrol, 2 individuals	GSE23307	normalized	GPL6104
GSE23307b	JAK-STAT	primary B cells	BTO:0000776	treated with IFN-b	activating	3 h	1 replicate each, respective timecontrol, 2 individuals	GSE23307	normalized	GPL6104
GSE23307c	JAK-STAT	primary monocytes	BTO:0000876	treated with IFN-b	activating	3 h	1 replicate each, respective timecontrol, 2 individuals	GSE23307	normalized	GPL6104
GSE23591a	JAK-STAT	L1236 lymphoma derived cell line	BTO:0000104	treated with 40 ng/ml IL-13	activating	0.5 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591b	JAK-STAT	L1236 lymphoma derived cell line	BTO:0000104	treated with 40 ng/ml IL-13	activating	1 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591c	JAK-STAT	L1236 lymphoma derived cell line	BTO:0000104	treated with 40 ng/ml IL-13	activating	1.5 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591d	JAK-STAT	L1236 lymphoma derived cell line	BTO:0000104	treated with 40 ng/ml IL-13	activating	2 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591e	JAK-STAT	L1236 lymphoma derived cell line	BTO:0000104	treated with 40 ng/ml IL-13	activating	3 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591f	JAK-STAT	L1236 lymphoma derived cell line	BTO:0000104	treated with 40 ng/ml IL-13	activating	4 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591g	JAK-STAT	L1236 lymphoma derived cell line	BTO:0000104	treated with 40 ng/ml IL-13	activating	6 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591h	JAK-STAT	MedB1 lymphoma derived cell line	BTO:0000104	treated with 20 ng/ml IL-13	activating	0.5 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591i	JAK-STAT	MedB1 lymphoma derived cell line	BTO:0000104	treated with 20 ng/ml IL-13	activating	1 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591j	JAK-STAT	MedB1 lymphoma derived cell line	BTO:0000104	treated with 20 ng/ml IL-13	activating	1.5 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591k	JAK-STAT	MedB1 lymphoma derived cell line	BTO:0000104	treated with 20 ng/ml IL-13	activating	2 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591l	JAK-STAT	MedB1 lymphoma derived cell line	BTO:0000104	treated with 20 ng/ml IL-13	activating	3 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591m	JAK-STAT	MedB1 lymphoma derived cell line	BTO:0000104	treated with 20 ng/ml IL-13	activating	4 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE23591n	JAK-STAT	MedB1 lymphoma derived cell line	BTO:0000104	treated with 20 ng/ml IL-13	activating	6 h	1 replicate, timeresolved controls, part of timeseries	GSE23591	log	GPL6244
GSE24403a	JAK-STAT	dermal fibroblasts	BTO:0001255	treated with 50 nM IL-13	activating	2 h	3 replicates control, 1 replicate treatment, part of timeseries	GSE24403	log	GPL6480
GSE24403b	JAK-STAT	dermal fibroblasts	BTO:0001255	treated with 50 nM IL-13	activating	4 h	3 replicates control, 1 replicate treatment, part of timeseries	GSE24403	log	GPL6480
GSE24409a	JAK-STAT	dermal fibroblasts	BTO:0001255	treated with 50 nM IL-4	activating	2 h	3 replicates control, 1 replicate treatment, part of timeseries	GSE24409	log	GPL6480
GSE24409b	JAK-STAT	dermal fibroblasts	BTO:0001255	treated with 50 nM IL-4	activating	4 h	3 replicates control, 1 replicate treatment, part of timeseries	GSE24409	log	GPL6480
GSE26949	JAK-STAT	peripheral blood EPCs/CACs	BTO:0003494	treated with IFNa	activating	6 h	6 replicates each	GSE26949	log	GPL11670
GSE26951	JAK-STAT	bone marrow EPCs	BTO:0004850	treated with IFNa	activating	6 h	5 replicates each	GSE26951	log	GPL11670
GSE31193	JAK-STAT	primary hepatocytes	BTO:0000575	treated with 10 U/ml IFN-a	activating	6 h	3 replicates	GSE31193	none	GPL570
GSE31264	JAK-STAT	primary hepatocytes	BTO:0000575	treated with 10 U/ml IFN-a	activating	6 h	1 replicate	GSE31264	none	GPL570
GSE3183	JAK-STAT	A549 (Human bronchial cell line)	BTO:0000018	treated with IL-13	activating	4 h	3 replicates each	GSE3183	log	GPL96
GSE33264a	JAK-STAT	Calu-3 cells	BTO:0002750	treated with 1000 U/ml IFNa	activating	3 h	3 replicates each, part of timeseries with 2 treatment conditions	GSE33264	normalized	GPL4133
GSE33264b	JAK-STAT	Calu-3 cells	BTO:0002750	treated with 1000 U/ml IFNa	activating	6 h	3 replicates each, part of timeseries with 2 treatment conditions	GSE33264	normalized	GPL4133
GSE33264c	JAK-STAT	Calu-3 cells	BTO:0002750	treated with 500 U/ml IFNg	activating	3 h	3 replicates each, part of timeseries with 2 treatment conditions	GSE33264	normalized	GPL4133
GSE33264d	JAK-STAT	Calu-3 cells	BTO:0002750	treated with 500 U/ml IFNg	activating	6 h	3 replicates each, part of timeseries with 2 treatment conditions	GSE33264	normalized	GPL4133
GSE3920a	JAK-STAT	HUVECs	BTO:0001949	treated with IFNa	activating	5 h	5 replicates	GSE3920	none	GPL96
GSE3920b	JAK-STAT	HUVECs	BTO:0001949	treated with IFNb	activating	5 h	2 replicates	GSE3920	none	GPL96
GSE3920c	JAK-STAT	HUVECs	BTO:0001949	treated with IFNg	activating	5 h	3 replicates	GSE3920	none	GPL96
GSE3920d	JAK-STAT	fibroblasts	BTO:0000452	treated with IFNa	activating	5 h	3 replicates	GSE3920	none	GPL96
GSE3920e	JAK-STAT	fibroblasts	BTO:0000452	treated with IFNg	activating	5 h	2 replicates	GSE3920	none	GPL96
GSE440	JAK-STAT	Foreskin keratinocytes	BTO:0001113	treated with IFN-gamma (respective timecontrol)	activating	1 h	2 Controls existent on the web page only 1 in the whole  download script just taken that one	GSE440	log	GPL8300
GSE4885a	JAK-STAT	HepG2 hepatocellular carcinoma cells	BTO:0000599	treated with IL-6	activating	1 h	2 replicates, part of timeseries	GSE4885	none	GPL96
GSE4885b	JAK-STAT	HepG2 hepatocellular carcinoma cells	BTO:0000599	treated with IL-6	activating	4 h	2 replicates, part of timeseries	GSE4885	none	GPL96
GSE5542a	JAK-STAT	A549 cell line	BTO:0000018	treated with 500U Infergen (Interferon type 1)	activating	6 h	4 replicates	GSE5542	none	GPL96
GSE5542b	JAK-STAT	A549 cell line	BTO:0000018	treated with 500U IFN-g1b	activating	6 h	4 replicates	GSE5542	none	GPL96
GSE8059	JAK-STAT	NK (Primary Natural Killer cells)	BTO:0000914	treated with IL-2	activating	2 h	NA	GSE8059	log	GPL570
GSE8515	JAK-STAT	human monocyte-derived macrophages	BTO:0000801	treated with IL-6	activating	4 h	5 replicates each	GSE8515	log	GPL96
GSE8685a	JAK-STAT	Sez-4 cell line	BTO:0001586	treated with 200U IL-2	activating	4 h	3 replicates, different IL treatments, after 16h IL2 starvation	GSE8685	none	GPL570
GSE8685b	JAK-STAT	Sez-4 cell line	BTO:0001586	treated with 20ng/ml IL-15	activating	4 h	3 replicates, different IL treatments, after 16h IL2 starvation	GSE8685	none	GPL570
GSE8685c	JAK-STAT	Sez-4 cell line	BTO:0001586	treated with 100ng/ml IL-21	activating	4 h	3 replicates, different IL treatments, after 16h IL2 starvation	GSE8685	none	GPL570
GSE8687	JAK-STAT	Sez-4	BTO:0001586	starved of IL-2 and activated with IL-2	activating	4 h after stimulation (16 h IL-2 pre-starvation)	NA	GSE8687	log	GPL570
GSE9481	JAK-STAT	side population of ovarian cancer	BTO:0001023	treated with 1000 U/ml IFNa	activating	5 h	2 replicates	GSE9481	none	GPL570
GSE10088a	MAPK	SkMel-28 cells	BTO:0002130	treated with PD0325901, MEK inhibitor	inhibiting	2 h	1 replicate each, mainly influencing MAPKs	GSE10088	none	GPL571
GSE10088b	MAPK	SkMel-28 cells	BTO:0002130	treated with PD0325901, MEK inhibitor	inhibiting	8 h	1 replicate each, mainly influencing MAPKs	GSE10088	none	GPL571
GSE12764	MAPK	MCF10A cells	BTO:0001939	transfected with MEK1	activating	24 h	6 replicates each, mostly activates MAPKs	GSE12764	none	GPL570
GSE14934b	MAPK	HEK-HT (kidney)	BTO:0000007	Ras (G12V,T35S) activation mutants	activating	not specified	mutants said to be mostly activating Raf	GSE14934	log	GPL571
GSE17939	MAPK	HUVECs	BTO:0001949	transfected with constitutive active MEK5D	activating	40 h	3 replicates each, mainly activating MAPKs	GSE17939	none	GPL570
GSE3542b	MAPK	MCF-7 (breast cancer cells)	BTO:0000093	co-transfected with constituitively active MEK	activating	not specified	two controls empty vector control taken	GSE3542	nolog	GPL96
GSE3542c	MAPK	MCF-7 (breast cancer cells)	BTO:0000093	co-transfected with constituitively active Raf	activating	not specified	two controls empty vector control taken	GSE3542	nolog	GPL96
GSE6521a	MAPK	MCF-7 breast cancer cells	BTO:0000093	Treatment with U0126 (MEK inhibitor)	inhibiting	1.5 h	no stimulation	GSE6521	log	GPL570
GSE10316	NFkB	monocyte-derived dendritic cells	BTO:0002900	treated with LPS 1 µg/ml	activating	4 h	immature cells	GSE10316	log	GPL570
GSE10316a	NFkB	monocyte derived dendritic cells	BTO:0002900	treated with 1 Âµg/ml LPS	activating	4 h	1 replicate each	GSE10316	none	GPL570
GSE10316b	NFkB	monocyte derived dendritic cells	BTO:0002900	treated with 50 Âµg/ml polyI:C	activating	4 h	1 replicate each	GSE10316	none	GPL570
GSE14000a	NFkB	primary blood cells	BTO:0000089	treated with LPS	activating	4 h	1 replicate each, 4 donors	GSE14000	none	GPL570
GSE14000b	NFkB	primary blood cells	BTO:0000089	treated with LPS	activating	4 h	1 replicate each, 4 donors	GSE14000	none	GPL570
GSE14000c	NFkB	primary blood cells	BTO:0000089	treated with LPS	activating	4 h	1 replicate each, 4 donors	GSE14000	none	GPL570
GSE14000d	NFkB	primary blood cells	BTO:0000089	treated with LPS	activating	4 h	1 replicate each, 4 donors	GSE14000	none	GPL570
GSE14419a	NFkB	primary macrophages	BTO:0000801	treated with zymosan A	activating	3 h	1 replicate each, 4 donors	GSE14419	none	GPL571
GSE14419b	NFkB	primary macrophages	BTO:0000801	treated with zymosan A	activating	3 h	1 replicate each, 4 donors	GSE14419	none	GPL571
GSE14419c	NFkB	primary macrophages	BTO:0000801	treated with zymosan A	activating	3 h	1 replicate each, 4 donors	GSE14419	none	GPL571
GSE14419d	NFkB	primary macrophages	BTO:0000801	treated with zymosan A	activating	3 h	1 replicate each, 4 donors	GSE14419	none	GPL571
GSE1541aNFkB	NFkB	A549 (Alveolar Epithelial Cells line)	BTO:0000018	treated with LPS	activating	1 h	NA	GSE1541	log	GPL201
GSE1541bNFkB	NFkB	A549 (Alveolar Epithelial Cells line)	BTO:0000018	treated with LPS	activating	4 h	NA	GSE1541	log	GPL201
GSE16193	NFkB	THP1 monocytic cell line	BTO:0001370	treated with  1 Âµg/ml LPS	activating	1 h	5 replicates each	GSE16193	non	GPL570
GSE18047a	NFkB	H929 (Multiple Myeloma Cell Line)	BTO:0002416	transfected with NIK	activating	undefined	overexpression directly above NFkB	GSE18047	nolog	GPL570
GSE18047b	NFkB	H929 (Multiple Myeloma Cell Line)	BTO:0002416	transfected with IKKB	activating	undefined	overexpression directly above NFkB	GSE18047	nolog	GPL570
GSE18047c	NFkB	SACHI (Multiple Myeloma Cell Line)	BTO:0002062	transfected with NIK	activating	undefined	overexpression directly above NFkB	GSE18047	nolog	GPL570
GSE18047d	NFkB	SACHI (Multiple Myeloma Cell Line)	BTO:0002062	transfected with IKKB	activating	undefined	overexpression directly above NFkB	GSE18047	nolog	GPL570
GSE19315	NFkB	THP1 monocytic cell line	BTO:0001370	treated with LPS	activating	6 h	3 replicates each	GSE19315	non	GPL570
GSE19627	NFkB	THP1 monocytes	BTO:0001370	treated with  LPS	activating	4 h	3 replicates each	GSE19627	log	GPL570
GSE19738a	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738a2	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738a3	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738a4	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738a6	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738a7	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738a8	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738a9	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738b	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738c	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738d	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738e	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738f	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738g	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738h	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738i	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738j	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738k	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738l	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738m	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738n	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738o	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738p	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738q	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738r	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738s	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738t	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738v	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738w	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738x	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738y	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE19738z	NFkB	whole blood cells	BTO:0000089	treated with LPS	activating	5-6 h	1 replicate each, 34 individuals	GSE19738	log	GPL6848
GSE20114a	NFkB	primary blood cells	BTO:0000089	treated with LPS	activating	4 h	1 replicate each, 4 donors	GSE20114	log	GPL570
GSE20114b	NFkB	primary blood cells	BTO:0000089	treated with LPS	activating	4 h	1 replicate each, 4 donors	GSE20114	log	GPL570
GSE20114c	NFkB	primary blood cells	BTO:0000089	treated with LPS	activating	4 h	1 replicate each, 4 donors	GSE20114	log	GPL570
GSE20114d	NFkB	primary blood cells	BTO:0000089	treated with LPS	activating	4 h	1 replicate each, 4 donors	GSE20114	log	GPL570
GSE22248a	NFkB	PBMCs	BTO:0001025	treated with LPS	activating	4 h	1 replicates each, 4 individuals	GSE22248	normalized	GPL6883
GSE22248b	NFkB	PBMCs	BTO:0001025	treated with LPS	activating	4 h	1 replicates each, 4 individuals	GSE22248	normalized	GPL6883
GSE22248c	NFkB	PBMCs	BTO:0001025	treated with LPS	activating	4 h	1 replicates each, 4 individuals	GSE22248	normalized	GPL6883
GSE22248d	NFkB	PBMCs	BTO:0001025	treated with LPS	activating	4 h	1 replicates each, 4 individuals	GSE22248	normalized	GPL6883
GSE23371	NFkB	dendritic cells	BTO:0002042	treated with LPS	activating	6 h	3 technical replicates each	GSE23371	log	GPL570
GSE2396	NFkB	human gammadelta T cells	BTO:0000782	treated with LPS	activating	4 h	4 cell cultures pooled	GSE2396	none	GPL571
GSE24897	NFkB	macrophages	BTO:0000801	treated with  PG-LPS	activating	2 h	3 replicates each	GSE24897	normalized	GPL570
GSE25155a	NFkB	HEK TLR2 transfected	BTO:0000007	treated with 10Âµg/ml H. pylori LPS	activating	2 h	2 replicates each, part of timeseries	GSE25155	log	GPL570
GSE2706	NFkB	Monocyte derived dendritic cells	BTO:0002900	treated with LPS	activating	2 h	3 replicates	GSE2706	log	GPL570
GSE29700	NFkB	BL-2 burkitt lymphoma cell line	BTO:0002748	treated with LPS	activating	6 h	3 replicates each	GSE29700	normalized	GPL570
GSE3037a	NFkB	primary periphal blood neutrophils	BTO:0000130	treated with LPS	activating	1 h	1 replicate each, 8 individuals	GSE3037	none	GPL96
GSE3037b	NFkB	primary periphal blood neutrophils	BTO:0000130	treated with LPS	activating	1 h	1 replicate each, 8 individuals	GSE3037	none	GPL96
GSE3037c	NFkB	primary periphal blood neutrophils	BTO:0000130	treated with LPS	activating	1 h	1 replicate each, 8 individuals	GSE3037	none	GPL96
GSE3037d	NFkB	primary periphal blood neutrophils	BTO:0000130	treated with LPS	activating	1 h	1 replicate each, 8 individuals	GSE3037	none	GPL96
GSE3037e	NFkB	primary periphal blood neutrophils	BTO:0000130	treated with LPS	activating	1 h	1 replicate each, 8 individuals	GSE3037	none	GPL96
GSE3037f	NFkB	primary periphal blood neutrophils	BTO:0000130	treated with LPS	activating	1 h	1 replicate each, 8 individuals	GSE3037	none	GPL96
GSE3037g	NFkB	primary periphal blood neutrophils	BTO:0000130	treated with LPS	activating	1 h	1 replicate each, 8 individuals	GSE3037	none	GPL96
GSE3037h	NFkB	primary periphal blood neutrophils	BTO:0000130	treated with LPS	activating	1 h	1 replicate each, 8 individuals	GSE3037	none	GPL96
GSE3140a	NFkB	mononuclear cells from adult peripheral blood	BTO:0001025	treated with 5 Âµg/ml LPS	activating	4 h	3 replicates each, timemight not be exact but probably 4h or 2h	GSE3140	none	GPL201
GSE3140b	NFkB	mononuclear cells from cord blood	BTO:0004053	treated with 5 Âµg/ml LPS	activating	4 h	3 replicates each, timemight not be exact but probably 4h or 2h	GSE3140	none	GPL201
GSE32390aNFkB	NFkB	fibroblasts	BTO:0000452	treated with poly I:C	activating	4 h	1 replicate each, 3 individuals	GSE32390	normalized	GPL10558
GSE32390bNFkB	NFkB	fibroblasts	BTO:0000452	treated with poly I:C	activating	4 h	1 replicate each, 3 individuals	GSE32390	normalized	GPL10558
GSE32390cNFkB	NFkB	fibroblasts	BTO:0000452	treated with poly I:C	activating	4 h	1 replicate each, 3 individuals	GSE32390	normalized	GPL10558
GSE32390dNFkB	NFkB	PBMCs	BTO:0001025	treated with 10 ng/ml LPS	activating	2 h	1 replicate each	GSE32390	normalized	GPL10558
GSE32390e	NFkB	PBMCs	BTO:0001025	treated with 3 Âµg/ml R848	activating	2 h	1 replicate each, R848 is a relative specific TLR7/8 agonist	GSE32390	normalized	GPL10558
GSE3491a	NFkB	GENDER: MALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH	BTO:0000089	treated with LPS 10 NG/ML	activating	4 h	three patients with high LPS response rate	GSE3491	nolog	GPL8300
GSE3491b	NFkB	GENDER: MALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH	BTO:0000089	treated with LPS 10 NG/ML	activating	4 h	three patients with high LPS response rate	GSE3491	nolog	GPL8300
GSE3491c	NFkB	GENDER: FEMALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH	BTO:0000089	treated with LPS 10 NG/ML	activating	4 h	three patients with high LPS response rate	GSE3491	nolog	GPL8300
GSE3720a	NFkB	expanded peripheral blood Vd1 gd T lymphocytes	BTO:0004729	treated with LPS 10 mg/mL	activating	4 h	3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL	GSE3720	log	GPL571
GSE3720b	NFkB	expanded peripheral blood Vd2 gd T lymphocytes	BTO:0004729	treated with LPS 10 mg/mL	activating	4 h	3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL	GSE3720	log	GPL571
GSE3982	NFkB	macrophages derived from monocytes	BTO:0000801	treated with LPS	activating	4 h	2 replicates each	GSE3982	none	GPL96
GSE3982a	NFkB	Human CD16+, CCR3- peripheral blood neutrophils	BTO:0000130	treated with LPS 100 ng/ml	activating	1 h	NA	GSE3982	log	GPL96
GSE3982b	NFkB	Macrophages differentiated from isolated CD14+ monocytes in the presence of GM-CSF	BTO:0000801	treated with LPS 100 ng/ml	activating	4 h	NA	GSE3982	log	GPL96
GSE4748	NFkB	Monocyte derived dendritic cells	BTO:0002900	treated with LPS 0.5 µg/ml	activating	3 h	NA	GSE4748	nolog	GPL570
GSE5504a	NFkB	human peripheral blood derived monocytes	BTO:0000876	treated with LPS	activating	2 h	NA	GSE5504	nolog	GPL570
GSE5504b	NFkB	human peripheral blood derived monocytes	BTO:0000876	treated with LPS	activating	4 h	NA	GSE5504	nolog	GPL570
GSE5883	NFkB	HMVEC-L (Microvascular endothelial cells, lung)	BTO:0002828	treated with LPS 10 ng	activating	4 h	4 replicates each	GSE5883	log	GPL570
GSE7850a	NFkB	Retinal endothelial cell	BTO:0001175	treated with LPS 10 100 ng/mL	activating	4 h	three different patients 2 different tissues	GSE7850	nolog	GPL201
GSE7850b	NFkB	Choroidal endothelial cell	BTO:0000439	treated with LPS 10 100 ng/mL	activating	4 h	three different patients 2 different tissues	GSE7850	nolog	GPL201
GSE7850c	NFkB	Retinal endothelial cell	BTO:0001175	treated with LPS 10 100 ng/mL	activating	4 h	three different patients 2 different tissues	GSE7850	nolog	GPL201
GSE7850d	NFkB	Choroidal endothelial cell	BTO:0000439	treated with LPS 10 100 ng/mL	activating	4 h	three different patients 2 different tissues	GSE7850	nolog	GPL201
GSE7850e	NFkB	Retinal endothelial cell	BTO:0001175	treated with LPS 10 100 ng/mL	activating	4 h	three different patients 2 different tissues	GSE7850	nolog	GPL201
GSE7850f	NFkB	Choroidal endothelial cell	BTO:0000439	treated with LPS 10 100 ng/mL	activating	4 h	three different patients 2 different tissues	GSE7850	nolog	GPL201
GSE8190a	NFkB	epithelial cells	BTO:0000419	treated with LPS	activating	4 h	2 replicates each, 14 individuals	GSE8190	log	GPL1708
GSE8190c	NFkB	epithelial cells	BTO:0000419	treated with LPS	activating	4 h	2 replicates each, 14 individuals	GSE8190	log	GPL1708
GSE8190d	NFkB	epithelial cells	BTO:0000419	treated with LPS	activating	4 h	2 replicates each, 14 individuals	GSE8190	log	GPL1708
GSE8190e	NFkB	epithelial cells	BTO:0000419	treated with LPS	activating	4 h	2 replicates each, 14 individuals	GSE8190	log	GPL1708
GSE8190f	NFkB	epithelial cells	BTO:0000419	treated with LPS	activating	4 h	2 replicates each, 14 individuals	GSE8190	log	GPL1708
GSE8190g	NFkB	epithelial cells	BTO:0000419	treated with LPS	activating	4 h	2 replicates each, 14 individuals	GSE8190	log	GPL1708
GSE8190h	NFkB	epithelial cells	BTO:0000419	treated with LPS	activating	4 h	2 replicates each, 14 individuals	GSE8190	log	GPL1708
GSE8190i	NFkB	epithelial cells	BTO:0000419	treated with LPS	activating	4 h	2 replicates each, 14 individuals	GSE8190	log	GPL1708
GSE8190k	NFkB	epithelial cells	BTO:0000419	treated with LPS	activating	4 h	2 replicates each, 14 individuals	GSE8190	log	GPL1708
GSE8190l	NFkB	epithelial cells	BTO:0000419	treated with LPS	activating	4 h	2 replicates each, 14 individuals	GSE8190	log	GPL1708
GSE8608	NFkB	monocyte-derived macrophages of 13 male healthy subjects	BTO:0000801	treated with LPS 10ng/ml	activating	4 h	NA	GSE8608	nolog	GPL570
GSE9916	NFkB	THP-1 cell line	BTO:0001370	treated with 1 Âµg/ml LPS	activating	4 h	3 replicates each	GSE9916	normalized	GPL570
GSE9988a	NFkB	Human monocytes (donor 1)	BTO:0000876	treated with LPS	activating	2 h	10 anonymous donors in this set	GSE9988	log	GPL570
GSE9988b	NFkB	Human monocytes (donor 2)	BTO:0000876	treated with LPS	activating	2 h	10 anonymous donors in this set	GSE9988	log	GPL570
GSE9988c	NFkB	Human monocytes (donor 3)	BTO:0000876	treated with LPS	activating	2 h	10 anonymous donors in this set	GSE9988	log	GPL570
GSE9988d	NFkB	Human monocytes (donor 4)	BTO:0000876	treated with LPS	activating	2 h	10 anonymous donors in this set	GSE9988	log	GPL570
GSE9988e	NFkB	Human monocytes (donor 5)	BTO:0000876	treated with LPS	activating	2 h	10 anonymous donors in this set	GSE9988	log	GPL570
GSE9988f	NFkB	Human monocytes (donor 6)	BTO:0000876	treated with LPS	activating	2 h	10 anonymous donors in this set	GSE9988	log	GPL570
GSE9988g	NFkB	Human monocytes (donor 7)	BTO:0000876	treated with LPS	activating	2 h	10 anonymous donors in this set	GSE9988	log	GPL570
GSE9988h	NFkB	Human monocytes (donor 8)	BTO:0000876	treated with LPS	activating	2 h	10 anonymous donors in this set	GSE9988	log	GPL570
GSE9988i	NFkB	Human monocytes (donor 9)	BTO:0000876	treated with LPS	activating	2 h	10 anonymous donors in this set	GSE9988	log	GPL570
GSE9988j	NFkB	Human monocytes (donor 11)	BTO:0000876	treated with LPS	activating	2 h	10 anonymous donors in this set	GSE9988	log	GPL570
GSE10086a	PI3K	MDA468 cells	BTO:0001570	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE10086b	PI3K	H1650 cells	BTO:0005243	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE10086c	PI3K	A431 cells	BTO:0000017	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE10086d	PI3K	BT474 cells	BTO:0001932	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE10086e	PI3K	SKBR3 cells	BTO:0002419	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE10086f	PI3K	COLO205 cells	BTO:0000179	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE10086g	PI3K	HT29 cells	BTO:0000182	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE10086h	PI3K	MALME3M cells	BTO:0004162	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE10086i	PI3K	SKMEL1 cells	BTO:0002130	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE10086j	PI3K	SKMEL5 cells	BTO:0002134	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE10086k	PI3K	SKMEL19 cells	BTO:0002130	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE10086l	PI3K	SKMEL28 cells	BTO:0002130	treated with PD0325901, MEK inhibitor	activating	8 h	1 replicate each, mainly activating PI3K pathway, 12 different cell lines	GSE10086	none	GPL571
GSE14934c	PI3K	HEK-HT (kidney)	BTO:0000007	Ras (G12V,Y40C) activation mutants	activating	not specified	mutants said to be mostly activating PI3K	GSE14934	log	GPL571
GSE17785a	PI3K	MCF10A cells	BTO:0001939	PI3K activated mutants	activating	not indicated	3 replicates each	GSE17785	normalized	GPL570
GSE17785b	PI3K	MCF10A cells	BTO:0001939	treated with GDC-0941. a PI3K inhibitor	inhibiting	4 h	3 replicates each	GSE17785	normalized	GPL570
GSE26599	PI3K	HB4a cells	BTO:0003893	treated with rapamycin	inhibiting	not indicated	5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway	GSE26599	none	GPL570
GSE3737	PI3K	PC3 (prostate cancer cell)	BTO:0001061	treatment with arachidonic acid (AA) should activate PI3K	activating	2 h	sveral microarrays! the ones taken from the same timeand microarray batch	GSE3737	log	GPL96
GSE6521b	PI3K	MCF-7 breast cancer cells	BTO:0000093	Treatment with U0126 (MEK inhibitor) + HRG (heregulin ErbB3 Ligand)	activating	0.75 h	besides PI3K also all non Raf Ras targets activated	GSE6521	log	GPL570
GSE6521c	PI3K	MCF-7 breast cancer cells	BTO:0000093	Treatment with U0126 (MEK inhibitor) + HRG (heregulin ErbB3 Ligand)	activating	1.5 h	besides PI3K also all non Raf Ras targets activated	GSE6521	log	GPL570
GSE7403b	PI3K	SH-SY5Y (Neuroblastoma cells)	BTO:0000793	PDGF treatment with 60 min prior U0126 treatment	activating	0.5 h	timeseries with 30, 60, 120, 240 min	GSE7403	log	GPL96
GSE7403d	PI3K	SH-SY5Y (Neuroblastoma cells)	BTO:0000793	PDGF treatment with 60 min prior U0126 treatment	activating	1 h	timeseries with 30, 60, 120, 240 min	GSE7403	log	GPL96
GSE7403f	PI3K	SH-SY5Y (Neuroblastoma cells)	BTO:0000793	PDGF treatment with 60 min prior U0126 treatment	activating	2 h	timeseries with 30, 60, 120, 240 min	GSE7403	log	GPL96
GSE7403h	PI3K	SH-SY5Y (Neuroblastoma cells)	BTO:0000793	PDGF treatment with 60 min prior U0126 treatment	activating	4 h	timeseries with 30, 60, 120, 240 min	GSE7403	log	GPL96
GSE7562a	PI3K	A431	BTO:0000017	PTEN hcRNA knockdown	activating	not specified (until log Phase)	NA	GSE7562	log	GPL570
GSE7562b	PI3K	HCC827	BTO:0004082	PTEN hcRNA knockdown	activating	not specified (until log Phase)	NA	GSE7562	log	GPL570
GSE7562c	PI3K	SKBR3	BTO:0002419	PTEN hcRNA knockdown	activating	not specified (until log Phase)	NA	GSE7562	log	GPL570
GSE15483a	PPAR	HUVECs	BTO:0001949	treated with 25 Âµmol fenofibrate, a PPARa ligand	activating	2 h	3 replicates each, timeseries	GSE15483	normalized	GPL4044
GSE15483b	PPAR	HUVECs	BTO:0001949	treated with 25 Âµmol fenofibrate, a PPARa ligand	activating	4 h	3 replicates each, timeseries	GSE15483	normalized	GPL4044
GSE15483c	PPAR	HUVECs	BTO:0001949	treated with 25 Âµmol fenofibrate, a PPARa ligand	activating	6 h	3 replicates each, timeseries	GSE15483	normalized	GPL4044
GSE16385a	PPAR	primary monocytes	BTO:0000876	treated with 1mM rosiglitazone, a PPARg agonist	activating	4 h	1 replicate each, differently activated macrophages	GSE16385	normalized	GPL570
GSE16385b	PPAR	primary IL4 activated monocytes	BTO:0000876	treated with 1mM rosiglitazone, a PPARg agonist	activating	4 h	1 replicate each, differently activated macrophages	GSE16385	normalized	GPL570
GSE16385c	PPAR	primary IFNg/TNFa activated monocytes	BTO:0000876	treated with 1mM rosiglitazone, a PPARg agonist	activating	4 h	1 replicate each, differently activated macrophages	GSE16385	normalized	GPL570
GSE16386a	PPAR	primary IL4 activated monocytes	BTO:0000876	treated with 100 ng/ml rosiglitazone, a PPARg agonist	activating	6 h	2 replicates each, 2 donors	GSE16386	normalized	GPL570
GSE16386b	PPAR	primary IL4 activated monocytes	BTO:0000876	treated with 100 ng/ml rosiglitazone, a PPARg agonist	activating	6 h	2 replicates each, 2 donors	GSE16386	normalized	GPL570
GSE17251a	PPAR	primary hepatocytes	BTO:0000575	treated with 50ÂµM Wy14643, a PPARa agonist	activating	6 h	1 replicate each, 6 donors	GSE17251	log	GPL570
GSE17251b	PPAR	primary hepatocytes	BTO:0000575	treated with 50ÂµM Wy14643, a PPARa agonist	activating	6 h	1 replicate each, 6 donors	GSE17251	log	GPL570
GSE17251c	PPAR	primary hepatocytes	BTO:0000575	treated with 50ÂµM Wy14643, a PPARa agonist	activating	6 h	1 replicate each, 6 donors	GSE17251	log	GPL570
GSE17251d	PPAR	primary hepatocytes	BTO:0000575	treated with 50ÂµM Wy14643, a PPARa agonist	activating	6 h	1 replicate each, 6 donors	GSE17251	log	GPL570
GSE17251e	PPAR	primary hepatocytes	BTO:0000575	treated with 50ÂµM Wy14643, a PPARa agonist	activating	6 h	1 replicate each, 6 donors	GSE17251	log	GPL570
GSE17251f	PPAR	primary hepatocytes	BTO:0000575	treated with 50ÂµM Wy14643, a PPARa agonist	activating	6 h	1 replicate each, 6 donors	GSE17251	log	GPL570
GSE25547	PPAR	HepG2 cells	BTO:0000599	treated with 100nM GW7647, a PPARa agonist	activating	6 h	3 replicates each	GSE25547	log	GPL570
GSE5258PPAR	PPAR	MCF7 cells	BTO:0000093	treated with 10ÂµM rosiglitazone, a PPARg agonist	activating	6 h	2 replicates each	GSE5258	none	GPL3921
GSE8658a	PPAR	monocyte derived dendritic cells	BTO:0002900	treated with 1ÂµM rosiglitazone, a PPARg agonist	activating	6 h	1 replicate each, 6 donors	GSE8658	none	GPL570
GSE8658b	PPAR	monocyte derived dendritic cells	BTO:0002900	treated with 1ÂµM rosiglitazone, a PPARg agonist	activating	6 h	1 replicate each, 6 donors	GSE8658	none	GPL570
GSE8658c	PPAR	monocyte derived dendritic cells	BTO:0002900	treated with 1ÂµM rosiglitazone, a PPARg agonist	activating	6 h	1 replicate each, 6 donors	GSE8658	none	GPL570
GSE8658d	PPAR	monocyte derived dendritic cells	BTO:0002900	treated with 1ÂµM rosiglitazone, a PPARg agonist	activating	6 h	1 replicate each, 6 donors	GSE8658	none	GPL570
GSE8658e	PPAR	monocyte derived dendritic cells	BTO:0002900	treated with 1ÂµM rosiglitazone, a PPARg agonist	activating	6 h	1 replicate each, 6 donors	GSE8658	none	GPL570
GSE8658f	PPAR	monocyte derived dendritic cells	BTO:0002900	treated with 1ÂµM rosiglitazone, a PPARg agonist	activating	6 h	1 replicate each, 6 donors	GSE8658	none	GPL570
GSE14426a	RAR	pancreatic stellate cell line	BTO:0000183	treated with 1ÂµM all-trans retinoid acid	activating	0.5 h	3 replicates each, part of timeseries, timeresolved controls	GSE14426	normalized	GPL6102
GSE14426b	RAR	pancreatic stellate cell line	BTO:0000183	treated with 1ÂµM all-trans retinoid acid	activating	4 h	3 replicates each, part of timeseries, timeresolved controls	GSE14426	normalized	GPL6102
GSE14500a	RAR	HL60 neutrophil progenitor cells	BTO:0000738	treated with 1ÂµM all-trans retinoid acid	activating	2 h	1 replicate each, part of timeseries, timerespective control	GSE14500	log	GPL8300
GSE14500b	RAR	HL60 neutrophil progenitor cells	BTO:0000738	treated with 1ÂµM all-trans retinoid acid	activating	4 h	1 replicate each, part of timeseries, timerespective control	GSE14500	log	GPL8300
GSE19201	RAR	NB4 cells	BTO:0002136	treated with all-trans retinoid acid	activating	4 h	1 replicate each	GSE19201	normalized	GPL570
GSE22298a	RAR	primary epidermal karatinocytes	BTO:0000667	treated with 1ÂµM all-trans retinoid acid	activating	1 h	1 replicate each, part of timeseries, timeresolved controls	GSE22298	none	GPL571
GSE22298b	RAR	primary epidermal karatinocytes	BTO:0000667	treated with 1ÂµM all-trans retinoid acid	activating	4 h	1 replicate each, part of timeseries, timeresolved controls	GSE22298	none	GPL571
GSE24731	RAR	HL60 leukemia cells	BTO:0000738	treated with 100nM retinoid acid	activating	4 h	4 replicates each, contain control vector	GSE24731	log	GPL4133
GSE29213	RAR	NB4 leukemia cells	BTO:0002136	treated with 10nM retinoid acid	activating	4 h	4 replicates each, contain control vector	GSE29213	log	GPL10332
GSE13837a1	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	1 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837a2	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	2 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837a3	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	4 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837b1	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	1 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837b2	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	2 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837b3	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	4 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837c1	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	1 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837c2	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	2 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837c3	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	4 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837d1	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	1 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837d2	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	2 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837d3	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	4 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837e1	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	1 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837e2	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	2 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE13837e3	TGFb	primary synovial fibroblasts	BTO:0001336	treated with 10ng/ml TGF-beta	activating	4 h	1 replicate each, part of timeseries, several patients	GSE13837	none	GPL570
GSE14491	TGFb	MDA-MB-231 metastatic breast cell line	BTO:0000815	treated with 5Âµg/ml TGF-beta	activating	3 h	4 replicate each, transfected with shGFP	GSE14491	log	GPL570
GSE1724	TGFb	lung fibroblasts	BTO:0000764	treated with 4 ng/ml TGF-beta	activating	4 h	3 replicates each	GSE1724	none	GPL8300
GSE17708a	TGFb	A549 lung carcinoma cell line	BTO:0000018	treated with 5ng/ml TGF-beta	activating	0.5 h	3 replicates each, part of timeseries	GSE17708	log	GPL570
GSE17708b	TGFb	A549 lung carcinoma cell line	BTO:0000018	treated with 5ng/ml TGF-beta	activating	1 h	3 replicates each, part of timeseries	GSE17708	log	GPL570
GSE17708c	TGFb	A549 lung carcinoma cell line	BTO:0000018	treated with 5ng/ml TGF-beta	activating	2 h	3 replicates each, part of timeseries	GSE17708	log	GPL570
GSE17708d	TGFb	A549 lung carcinoma cell line	BTO:0000018	treated with 5ng/ml TGF-beta	activating	4 h	3 replicates each, part of timeseries	GSE17708	log	GPL570
GSE17860	TGFb	osteoblast cell line	BTO:0004324	treated with 10ng/ml TGF-beta	activating	6 h	3 replicates each	GSE17860	log	GPL4133
GSE1802a	TGFb	human umbilical cord blood CD34+ cells	BTO:0004053	treated with TGF-beta	activating	2 h	3 replicates each, part of timeseries	GSE1802	none	GPL96
GSE1802b	TGFb	human umbilical cord blood CD34+ cells	BTO:0004053	treated with TGF-beta	activating	4 h	4 replicates each, part of timeseries	GSE1802	none	GPL96
GSE1805a	TGFb	M091	BTO:0005491	treated with 10 ng/ml TGF-beta	activating	2 h	3 replicates each, part of timeseries	GSE1805	none	GPL8300
GSE1805b	TGFb	M091	BTO:0005491	treated with TGF-beta	activating	4 h	2 replicates each, part of timeseries	GSE1805	none	GPL8300
GSE23935a	TGFb	primary glioblastoma	BTO:0000527	treated with LY2109761, TGF-beta receptor inhibitor	inhibiting	3 h	1 replicate each	GSE23935	none	GPL570
GSE23935b	TGFb	primary glioblastoma	BTO:0000527	treated with LY2109761, TGF-beta receptor inhibitor	inhibiting	3 h	1 replicate each	GSE23935	none	GPL570
GSE23935c	TGFb	primary glioblastoma	BTO:0000527	treated with LY2109761, TGF-beta receptor inhibitor	inhibiting	3 h	1 replicate each	GSE23935	none	GPL570
GSE23935d	TGFb	primary glioblastoma	BTO:0000527	treated with LY2109761, TGF-beta receptor inhibitor	inhibiting	3 h	1 replicate each	GSE23935	none	GPL570
GSE23935e	TGFb	primary glioblastoma	BTO:0000527	treated with LY2109761, TGF-beta receptor inhibitor	inhibiting	3 h	1 replicate each	GSE23935	none	GPL570
GSE23935f	TGFb	primary glioblastoma	BTO:0000527	treated with LY2109761, TGF-beta receptor inhibitor	inhibiting	3 h	1 replicate each	GSE23935	none	GPL570
GSE23935g	TGFb	primary glioblastoma	BTO:0000527	treated with LY2109761, TGF-beta receptor inhibitor	inhibiting	3 h	1 replicate each	GSE23935	none	GPL570
GSE23935h	TGFb	primary glioblastoma	BTO:0000527	treated with LY2109761, TGF-beta receptor inhibitor	inhibiting	3 h	1 replicate each	GSE23935	none	GPL570
GSE23935i	TGFb	primary glioblastoma	BTO:0000527	treated with LY2109761, TGF-beta receptor inhibitor	inhibiting	3 h	1 replicate each	GSE23935	none	GPL570
GSE23935j	TGFb	primary glioblastoma	BTO:0000527	treated with LY2109761, TGF-beta receptor inhibitor	inhibiting	3 h	1 replicate each	GSE23935	none	GPL570
GSE23935k	TGFb	primary glioblastoma	BTO:0000527	treated with LY2109761, TGF-beta receptor inhibitor	inhibiting	3 h	1 replicate each	GSE23935	none	GPL570
GSE27526	TGFb	A2780	BTO:0002549	treated with 10ng/ml TGF-beta1	activating	3 h	3 replicates each	GSE27526	log	GPL570
GSE28590	TGFb	HepG2 hepatoblastoma cells	BTO:0000599	treated with 3ng/ml TGF-beta	activating	1.5 h	1 replicate each	GSE28590	none	GPL570
GSE30004a	TGFb	primary vascular smooth muscle cells	BTO:0001431	treated with 1ng/ml TGF-beta	activating	6 h	3 replicates each	GSE30004	none	GPL6244
GSE30004b	TGFb	primary vascular smooth muscle cells	BTO:0001431	treated with 1ng/ml TGF-beta	activating	6 h	3 replicates each	GSE30004	none	GPL6244
GSE30004c	TGFb	primary vascular smooth muscle cells	BTO:0001431	treated with 1ng/ml TGF-beta	activating	6 h	3 replicates each	GSE30004	none	GPL6244
GSE5150a	TGFb	CD34+ hematopoietic stem/progenitor cells	BTO:0000725	treated with TGF-beta	activating	2 h	1 replicate each, part of timeseries	GSE5150	none	GPL8300
GSE5150b	TGFb	CD34+ hematopoietic stem/progenitor cells	BTO:0000725	treated with TGF-beta	activating	4 h	1 replicate each, part of timeseries	GSE5150	none	GPL8300
GSE5151	TGFb	dendritic cells	BTO:0002042	treated with 10 ng/ml TGF-beta1	activating	4 h	1 replicate	GSE5151	none	GPL8300
GSE6653a	TGFb	IOSE - immortalized ovarian surface epithelial cells	BTO:0004130	treated with TGF-beta1	activating	3 h	2 replicates each, part of timeseries	GSE6653	none	GPL570
GSE6653b	TGFb	IOSE - immortalized ovarian surface epithelial cells	BTO:0004130	treated with TGF-beta1	activating	6 h	2 replicates each, part of timeseries	GSE6653	none	GPL570
GSE8730a	TGFb	odontoblasts	BTO:0001769	treated with TGF-beta1	activating	1 h	1 replicate	GSE8730	none	GPL570
GSE8730b	TGFb	pulp tissue	BTO:0000339	treated with TGF-beta1	activating	1 h	1 replicate, part of timeseries	GSE8730	none	GPL96
GSE8730c	TGFb	pulp tissue	BTO:0000339	treated with TGF-beta1	activating	5 h	1 replicate, part of timeseries	GSE8730	none	GPL96
GSE11115	TNFa	U3OS cells expressing additional estrogen receptor	BTO:0001938	treated with TNFa	activating	1h h	3-4 replicates each, doxycyline induction of ER expression	GSE11115	none	GPL96
GSE13206a	TNFa	HeLa cells	BTO:0000567	treated with 5 ng/ml TNFa	activating	1.5 h	1 replicate each, part of timeseries, shControl transfected	GSE13206	log	GPL7490
GSE13206b	TNFa	HeLa cells	BTO:0000567	treated with 5 ng/ml TNFa	activating	6 h	1 replicate each, part of timeseries, shControl transfected	GSE13206	log	GPL7490
GSE13837a	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	1 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837b	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	2 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837c	TNFa	synovial fibroblasts, female, age 65, rheumatoid arthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	4 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837d	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	1 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837e	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	2 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837f	TNFa	synovial fibroblasts, male, age 56, osteoarthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	4 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837g	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	1 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837h	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	2 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837i	TNFa	synovial fibroblasts, male, age 65, osteoarthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	4 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837j	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	1 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837k	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	2 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837l	TNFa	synovial fibroblasts, female, age 57, osteoarthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	4 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837m	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	1 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837n	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	2 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837o	TNFa	synovial fibroblasts, female, age 57, rheumatoid arthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	4 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837p	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	1 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837q	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	2 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE13837r	TNFa	synovial fibroblasts, female, age 67, rheumatoid arthritis	BTO:0001336	treated with TNFa 10 ng/ml	activating	4 h	always compared to the 0 h timepoint	GSE13837	log	GPL570
GSE1474a	TNFa	CaCo-2 (Colon cell line)	BTO:0000195	treated with TNFa	activating	4 h	3 replicates each	GSE1474	nolog	GPL96
GSE1474b	TNFa	T84	BTO:0002032	treated with TNFa	activating	4 h	3 replicates each	GSE1474	nolog	GPL96
GSE1541a	TNFa	A549 (Alveolar Epithelial Cells line)	BTO:0000018	treated with TNFa 20 ng/ml	activating	1 h	NA	GSE1541	log	GPL201
GSE1541b	TNFa	A549 (Alveolar Epithelial Cells line)	BTO:0000018	treated with TNFa 20 ng/ml	activating	4 h	NA	GSE1541	log	GPL201
GSE16251aTNFa	TNFa	primary PBMCs	BTO:0001025	treated with TNFa	activating	0.5 h	1 replicate each, part of timeseries, timerespective control	GSE16251	log	GPL8601
GSE16251bTNFa	TNFa	primary PBMCs	BTO:0001025	treated with TNFa	activating	1 h	1 replicate each, part of timeseries, timerespective control	GSE16251	log	GPL8601
GSE16251cTNFa	TNFa	primary PBMCs	BTO:0001025	treated with TNFa	activating	4 h	1 replicate each, part of timeseries, timerespective control	GSE16251	log	GPL8601
GSE16650	TNFa	Beas-B2 (Human Bronchial Epithelial Cells)	BTO:0002923	treated with TNFa 20 ng/ml	activating	4 h	2 replicates each	GSE16650	nolog	GPL570
GSE21727TNFa	TNFa	trabecular bone cells	BTO:0001700	treated with TNFa	activating	2 h	3 replicates each, timerespective control	GSE21727	normalized	GPL6104
GSE22807	TNFa	DU145 prostate cancer cells	BTO:0001332	treated with 10 ng/ml TNFa	activating	1.5 h	2 replicates each	GSE22807	none	GPL6244
GSE2489a	TNFa	Epidermis Keratinocytes	BTO:0000667	treated with TNFa	activating	1 h	NA	GSE2489	log	GPL8300
GSE2489b	TNFa	Epidermis Keratinocytes	BTO:0000667	treated with TNFa	activating	4 h	NA	GSE2489	log	GPL8300
GSE2624a	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	BTO:0000567	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	activating	1 h	mutant cell line	GSE2624	log	GPL8300
GSE2624b	TNFa	human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut	BTO:0000567	treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away	activating	3 h	mutant cell line	GSE2624	log	GPL8300
GSE2638	TNFa	HMECs	BTO:0002178	treated with 2ng/ml TNFa	activating	5 h	3 replicates each	GSE2638	none	GPL96
GSE2639	TNFa	HUVECs	BTO:0001949	treated with 2ng/ml TNFa	activating	5 h	4 replicates each	GSE2639	none	GPL96
GSE26868a	TNFa	HeLa cells	BTO:0000567	treated with 10 ng/ml TNFa	activating	2 h	2 replicates each, comparison 2 cell lines	GSE26868	log	GPL570
GSE26868b	TNFa	THP1 cells	BTO:0001370	treated with 10 ng/ml TNFa	activating	2 h	3 replicates each, comparison 2 cell lines	GSE26868	log	GPL570
GSE27870a	TNFa	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 10ng/ml TNFa	activating	1 h	3 replicates each, part of timeseries (1, 1.5, 2, 3, 4, 5, 6 h)	GSE27870	medianscaled	GPL4044
GSE27870b	TNFa	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 10ng/ml TNFa	activating	1.5 h	3 replicates each, part of timeseries (1, 1.5, 2, 3, 4, 5, 6 h)	GSE27870	medianscaled	GPL4044
GSE27870c	TNFa	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 10ng/ml TNFa	activating	2 h	3 replicates each, part of timeseries (1, 1.5, 2, 3, 4, 5, 6 h)	GSE27870	medianscaled	GPL4044
GSE27870d	TNFa	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 10ng/ml TNFa	activating	3 h	3 replicates each, part of timeseries (1, 1.5, 2, 3, 4, 5, 6 h)	GSE27870	medianscaled	GPL4044
GSE27870e	TNFa	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 10ng/ml TNFa	activating	4 h	3 replicates each, part of timeseries (1, 1.5, 2, 3, 4, 5, 6 h)	GSE27870	medianscaled	GPL4044
GSE27870f	TNFa	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 10ng/ml TNFa	activating	5 h	3 replicates each, part of timeseries (1, 1.5, 2, 3, 4, 5, 6 h)	GSE27870	medianscaled	GPL4044
GSE27870g	TNFa	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 10ng/ml TNFa	activating	6 h	3 replicates each, part of timeseries (1, 1.5, 2, 3, 4, 5, 6 h)	GSE27870	medianscaled	GPL4044
GSE28548	TNFa	HEK293 cells	BTO:0000007	treated with TNFa	activating	1 h	3 replicates each	GSE28548	normalized	GPL570
GSE516	TNFa	human arthritic synoviocytes	BTO:0004060	treated with TNFa	activating	4 h	NA	GSE516	log	GPL8300
GSE8166	TNFa	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treated with TNFa 1ng/ml cultured in M199 medium	activating	3 h	NA	GSE8166	log	GPL570
GSE9055a	TNFa	HUVEC (Human umbilical vein cells)	BTO:0001949	treated with TNFa 10 ng/ml after 18 h serum starvation	activating	0.5 h	timeseries every 15 min until 8 h	GSE9055	log	GPL570
GSE9055b	TNFa	HUVEC (Human umbilical vein cells)	BTO:0001949	treated with TNFa 10 ng/ml after 18 h serum starvation	activating	1 h	timeseries every 15 min until 8 h	GSE9055	log	GPL570
GSE9055c	TNFa	HUVEC (Human umbilical vein cells)	BTO:0001949	treated with TNFa 10 ng/ml after 18 h serum starvation	activating	2 h	timeseries every 15 min until 8 h	GSE9055	log	GPL570
GSE9055d	TNFa	HUVEC (Human umbilical vein cells)	BTO:0001949	treated with TNFa 10 ng/ml after 18 h serum starvation	activating	4 h	timeseries every 15 min until 8 h	GSE9055	log	GPL570
GSE32441a	Trail	HT1080 fibrosarcoma cells	BTO:0001282	treated with 50 ng/ml TRAIL	activating	6 h	1 replicate each, control and treated cells were additionally treated with 0.25 Âµg/ml doxorubicin	GSE32441	none	GPL4133
GSE32441b	Trail	HT1080 fibrosarcoma cells	BTO:0001282	treated with 50 ng/ml TRAIL	activating	6 h	1 replicate each, control and treated cells were additionally treated with 4 Âµg/ml trabectedin	GSE32441	none	GPL4133
GSE32441c	Trail	HT1080 fibrosarcoma cells	BTO:0001282	treated with 50 ng/ml TRAIL	activating	6 h	1 replicate each, control and treated cells were additionally treated with 1.5 Âµg/ml mafosfamide	GSE32441	none	GPL4133
GSE8346	Trail	T4-2 breat epithelial cells	BTO:0001211	treated with 1 Âµg/ml TRAIL	activating	4 h	4 replicates each, contain control vector, 3D culture	GSE8346	none	GPL571
GSE10778aVEGF	VEGF	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 100ng VEGF	activating	30 min	timeseries (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B	GSE10778	log	GPL96
GSE10778bVEGF	VEGF	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 100ng VEGF	activating	1 h	timeseries (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B	GSE10778	log	GPL96
GSE10778cVEGF	VEGF	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 100ng VEGF	activating	2.5 h	timeseries (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B	GSE10778	log	GPL96
GSE10778d	VEGF	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 100ng VEGF	activating	30 min	timeseries (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B	GSE10778	log	GPL97
GSE10778e	VEGF	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 100ng VEGF	activating	1 h	timeseries (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B	GSE10778	log	GPL97
GSE10778f	VEGF	HUVEC (human umbilical vein endothelial cells)	BTO:0001949	treatment with 100ng VEGF	activating	2.5 h	timeseries (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B	GSE10778	log	GPL97
GSE11228a	VEGF	LEC (Human dermal lymphatic endothelial cells)	BTO:0004167	treatment with VEGF-A165 (20ng/ml)	activating	1 h	timeseries (1, 4, 8, 24 h)	GSE11228	nolog	GPL2986
GSE11228b	VEGF	LEC (Human dermal lymphatic endothelial cells)	BTO:0004167	treatment with VEGF-A165 (20 ng/ml)	activating	4 h	timeseries (1, 4, 8, 24 h)	GSE11228	nolog	GPL2986
GSE11228c	VEGF	LEC (Human dermal lymphatic endothelial cells)	BTO:0004167	treatment with VEGF-C (500 ng/ml)	activating	1 h	timeseries (1, 4, 8, 24 h)	GSE11228	nolog	GPL2986
GSE11228d	VEGF	LEC (Human dermal lymphatic endothelial cells)	BTO:0004167	treatment with VEGF-C (500 ng/ml)	activating	4 h	timeseries (1, 4, 8, 24 h)	GSE11228	nolog	GPL2986
GSE15464a	VEGF	HUVECs	BTO:0001949	treated with 100ng/ml VEGF-A165	activating	30 min	1 replicate, part of timeseries	GSE15464	normalized	GPL570
GSE15464b	VEGF	HUVECs	BTO:0001949	treated with 100ng/ml VEGF-A165	activating	60 min	1 replicate, part of timeseries	GSE15464	normalized	GPL570
GSE15464c	VEGF	HUVECs	BTO:0001949	treated with 100ng/ml VEGF-A165	activating	150 min	1 replicate, part of timeseries	GSE15464	normalized	GPL570
GSE17777	VEGF	HMVECs	BTO:0002828	treated with 100pg/ml VEGF	activating	4 h	1 replicate	GSE17777	none	GPL570
GSE18913a	VEGF	HUVECs	BTO:0001949	treated with VEGF	activating	1 h	3 replicates, part of timeseries	GSE18913	none	GPL570
GSE18913b	VEGF	HUVECs	BTO:0001949	treated with VEGF	activating	4 h	3 replicates, part of timeseries	GSE18913	none	GPL570
GSE19335	VEGF	HUVECs	BTO:0001949	treated with 50ng/ml VEGF	activating	30 min	2 replicates	GSE19335	log	GPL6947
GSE3891a	VEGF	HMVEC (Human microvascular endothelial cells)	BTO:0002828	VEGF treatment	activating	30 min	timeseries 30 min, 1, 2, 4 h (same Experiments for 2 Chips HG-U133 A and B)	GSE3891	log	GPL96
GSE3891b	VEGF	HMVEC (Human microvascular endothelial cells)	BTO:0002828	VEGF treatment	activating	1 h	timeseries 30 min, 1, 2, 4 h (same Experiments for 2 Chips HG-U133 A and B)	GSE3891	log	GPL96
GSE3891c	VEGF	HMVEC (Human microvascular endothelial cells)	BTO:0002828	VEGF treatment	activating	2 h	timeseries 30 min, 1, 2, 4 h (same Experiments for 2 Chips HG-U133 A and B)	GSE3891	log	GPL96
GSE3891d	VEGF	HMVEC (Human microvascular endothelial cells)	BTO:0002828	VEGF treatment	activating	4 h	timeseries 30 min, 1, 2, 4 h (same Experiments for 2 Chips HG-U133 A and B)	GSE3891	log	GPL96
GSE3891e	VEGF	HMVEC (Human microvascular endothelial cells)	BTO:0002828	VEGF treatment	activating	30 min	timeseries 30 min, 1, 2, 4 h (same Experiments for 2 Chips HG-U133 A and B)	GSE3891	log	GPL97
GSE3891f	VEGF	HMVEC (Human microvascular endothelial cells)	BTO:0002828	VEGF treatment	activating	1 h	timeseries 30 min, 1, 2, 4 h (same Experiments for 2 Chips HG-U133 A and B)	GSE3891	log	GPL97
GSE3891g	VEGF	HMVEC (Human microvascular endothelial cells)	BTO:0002828	VEGF treatment	activating	2 h	timeseries 30 min, 1, 2, 4 h (same Experiments for 2 Chips HG-U133 A and B)	GSE3891	log	GPL97
GSE3891h	VEGF	HMVEC (Human microvascular endothelial cells)	BTO:0002828	VEGF treatment	activating	4 h	timeseries 30 min, 1, 2, 4 h (same Experiments for 2 Chips HG-U133 A and B)	GSE3891	log	GPL97
GSE837a	VEGF	HUVECs	BTO:0001949	treated with VEGF	activating	4 h	1 replicate, part of 3 different isolates	GSE837	none	GPL91
GSE837b	VEGF	HUVECs	BTO:0001949	treated with VEGF	activating	4 h	1 replicate, part of 3 different isolates	GSE837	none	GPL91
GSE837c	VEGF	HUVECs	BTO:0001949	treated with VEGF	activating	4 h	1 replicate, part of 3 different isolates	GSE837	none	GPL91
GSE11916	Wnt	Huh7 (hepatocellular carcinoma derived)	BTO:0001950	High TCF activity Huh7 cell line was compared to control Huh7 cell line (TCF the crucial transcription factor for Wnt)	activating	not specified	constitutive activation	GSE11916	log	GPL570
GSE14107a	Wnt	parental PC9 (Lung adenocarcinoma cell line)	BTO:0005518	Wnt3a stimulation after serum starvation (0.2 %)	activating	3 h	NA	GSE14107	log	GPL571
GSE14107b	Wnt	parental H2030 (Lung adenocarcinoma cell line)	BTO:0001911	Wnt3a stimulation after serum starvation (0.2 %)	activating	3 h	NA	GSE14107	log	GPL571
GSE1473	Wnt	HEK293 (kidney cell)	BTO:0000007	infected with RCAS-beta-cateninS37A or RCAS-GFP	activating	not specified	late and early response expected	GSE1473	log	GPL96
GSE17385	Wnt	Multiple myeloma line MM1.S	BTO:0003933	cells lentivirally infected with control shRNA or beta-catenin shRNA vectors	inhibiting	not specified	inhibition	GSE17385	nolog	GPL570
GSE24708	Wnt	HEK293, transfected with siControl plasmid	BTO:0000007	treated with Wnt3a	activating	7 h	2 replicates each	GSE24708	none	GPL10191
GSE26351	Wnt	mobilized periphal blood CD34+ cells	BTO:0003494	0.5 ÂµM BIO (GSK3 inhibitor)	activating	2 h	3 replicates, BIO activates WNT pathway	GSE26351	none	GPL570
GSE27313	Wnt	mesenchymal stem cells	BTO:0003298	treated with Wnt3a	activating	6 h	1 replicate each	GSE27313	none	GPL570
GSE10778a	both	human umbilical vein endothelial cells (HUVEC)	BTO:0001949	Treatment with EGF	activating	0.5 h	timeseries 30 min, 1 h, 2.5 h 6 h / same with VEGF	GSE10778	log	GPL96
GSE10778b	both	human umbilical vein endothelial cells (HUVEC)	BTO:0001949	Treatment with EGF	activating	1 h	timeseries 30 min, 1 h, 2.5 h 6 h / same with VEGF	GSE10778	log	GPL96
GSE10778c	both	human umbilical vein endothelial cells (HUVEC)	BTO:0001949	Treatment with EGF	activating	2.5 h	timeseries 30 min, 1 h, 2.5 h 6 h / same with VEGF	GSE10778	log	GPL96
GSE11729a	both	H1299 human non-small cell lung cancer cells	BTO:0002552	Treatment with EGF	activating	0.5 h	timeseries: 30 min, 1, 2, 4, 6 and 10 h	GSE11729	nolog	GPL570
GSE11729b	both	H1299 human non-small cell lung cancer cells	BTO:0002552	Treatment with EGF	activating	1 h	timeseries: 30 min, 1, 2, 4, 6 and 10 h	GSE11729	nolog	GPL570
GSE11729c	both	H1299 human non-small cell lung cancer cells	BTO:0002552	Treatment with EGF	activating	2 h	timeseries: 30 min, 1, 2, 4, 6 and 10 h	GSE11729	nolog	GPL570
GSE11729d	both	H1299 human non-small cell lung cancer cells	BTO:0002552	Treatment with EGF	activating	4 h	timeseries: 30 min, 1, 2, 4, 6 and 10 h	GSE11729	nolog	GPL570
GSE11729e	both	H1299 human non-small cell lung cancer cells	BTO:0002552	Treatment with EGF	activating	6 h	timeseries: 30 min, 1, 2, 4, 6 and 10 h	GSE11729	nolog	GPL570
GSE12764b	both	MCF10A cells	BTO:0001939	transfected with HRAS(G12V)	activating	24 h	3 replicates each, probably activating PI3K and MAPKs	GSE12764	none	GPL570
GSE13009a	both	MCF7 human breast cancer cells	BTO:0000093	Treatment with EGF	activating	0.5 h	timeseries: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h	GSE13009	log	GPL571
GSE13009b	both	MCF7 human breast cancer cells	BTO:0000093	Treatment with EGF	activating	1 h	timeseries: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h	GSE13009	log	GPL571
GSE13009c	both	MCF7 human breast cancer cells	BTO:0000093	Treatment with EGF	activating	2 h	timeseries: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h	GSE13009	log	GPL571
GSE13009d	both	MCF7 human breast cancer cells	BTO:0000093	Treatment with EGF	activating	4 h	timeseries: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h	GSE13009	log	GPL571
GSE13009e	both	MCF7 human breast cancer cells	BTO:0000093	Treatment with HRG	activating	0.5 h	timeseries: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h	GSE13009	log	GPL571
GSE13009f	both	MCF7 human breast cancer cells	BTO:0000093	Treatment with HRG	activating	1 h	timeseries: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h	GSE13009	log	GPL571
GSE13009g	both	MCF7 human breast cancer cells	BTO:0000093	Treatment with HRG	activating	2 h	timeseries: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h	GSE13009	log	GPL571
GSE13009h	both	MCF7 human breast cancer cells	BTO:0000093	Treatment with HRG	activating	4 h	timeseries: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h	GSE13009	log	GPL571
GSE13009i	both	MCF7 human breast cancer cells	BTO:0000093	Treatment with EGF	activating	6 h	timeseries: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h	GSE13009	log	GPL571
GSE13009j	both	MCF7 human breast cancer cells	BTO:0000093	Treatment with HRG	activating	6 h	timeseries: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h	GSE13009	log	GPL571
GSE13168a	both	airway smooth muscle cells	BTO:0001660	treated with EGF	activating	8 h	1 replicate each, contain control vector, 4 donors	GSE13168	normalized	GPL96
GSE13168b	both	airway smooth muscle cells	BTO:0001660	treated with EGF	activating	8 h	1 replicate each, contain control vector, 4 donors	GSE13168	normalized	GPL96
GSE13168c	both	airway smooth muscle cells	BTO:0001660	treated with EGF	activating	8 h	1 replicate each, contain control vector, 4 donors	GSE13168	normalized	GPL96
GSE13168d	both	airway smooth muscle cells	BTO:0001660	treated with EGF	activating	8 h	1 replicate each, contain control vector, 4 donors	GSE13168	normalized	GPL96
GSE14256a	both	Human foreskin fibroblasts (AG01518)	BTO:0001113	Treatment with platelet-derived growth factor-BB (PDGF-BB)	activating	1 h	NA	GSE14256	log	GPL571
GSE14256b	both	Human foreskin fibroblasts (AG01518)	BTO:0001113	Treatment with bFGF (basic fibroblast growth factor)	activating	1 h	NA	GSE14256	log	GPL571
GSE14934a	both	HEK-HT (kidney)	BTO:0000007	Ras (G12V) activation mutants	activating	not specified	NA	GSE14934	log	GPL571
GSE20277	both	HeLa cells	BTO:0000567	treated with EGF	activating	0.66 h	3 replicates each	GSE20277	log	GPL6480
GSE33710	both	WI-38 cells	BTO:0003066	RASv12 overexpression	activating	not indicated	3 replicates each	GSE33710	none	GPL96
GSE3542a	both	MCF-7 (breast cancer cells)	BTO:0000093	co-transfected with constituitively active erbB-2	activating	not specified	two controls empty vector control taken	GSE3542	nolog	GPL96
GSE3542d	both	MCF-7 (breast cancer cells)	BTO:0000093	co-transfected with ligand-inducible EGFR	activating	not specified	two controls empty vector control taken	GSE3542	nolog	GPL96
GSE6462a	both	MCF-7 (human breast cancer)	BTO:0000093	treatment with EGF (10nm)	activating	0.75 h	timeseries	GSE6462	log	GPL571
GSE6462b	both	MCF-7 (human breast cancer)	BTO:0000093	treatment with EGF (10nm)	activating	1.5 h	timeseries	GSE6462	log	GPL571
GSE6462c	both	MCF-7 (human breast cancer)	BTO:0000093	treatment with 10 nm HRG= heregulin Erb3/4 Ligand	activating	0.75 h	timeseries	GSE6462	log	GPL571
GSE6462d	both	MCF-7 (human breast cancer)	BTO:0000093	treatment with 10 nm HRG= heregulin Erb3/4 Ligand	activating	1.5 h	timeseries	GSE6462	log	GPL571
GSE6521d	both	MCF-7 breast cancer cells	BTO:0000093	Treatment with HRG (heregulin ErbB3 Ligand)	activating	0.75 h	NA	GSE6521	log	GPL570
GSE6521e	both	MCF-7 breast cancer cells	BTO:0000093	Treatment with HRG (heregulin ErbB3 Ligand)	activating	1.5 h	NA	GSE6521	log	GPL570
GSE6783a	both	HELA (Human cervical carcinoma cell line)	BTO:0000567	EGF treatment after 24 h serum starvation (Control 0 h)	activating	0.33 h	timeseries with 20, 40, 60, 120, 240, 480 min	GSE6783	log	GPL96
GSE6783b	both	HELA (Human cervical carcinoma cell line)	BTO:0000567	EGF treatment after 24 h serum starvation (Control 0 h)	activating	1 h	timeseries with 20, 40, 60, 120, 240, 480 min	GSE6783	log	GPL96
GSE6783c	both	HELA (Human cervical carcinoma cell line)	BTO:0000567	EGF treatment after 24 h serum starvation (Control 0 h)	activating	2 h	timeseries with 20, 40, 60, 120, 240, 480 min	GSE6783	log	GPL96
GSE6783d	both	HELA (Human cervical carcinoma cell line)	BTO:0000567	EGF treatment after 24 h serum starvation (Control 0 h)	activating	4 h	timeseries with 20, 40, 60, 120, 240, 480 min	GSE6783	log	GPL96
GSE6784a	both	MCF-10A (mammary epithelial cell line)	BTO:0001939	EGF treatment after 24 h serum starvation (Control 0 h)	activating	0.33 h	timeseries with 20, 40, 60, 120, 240, 480 min	GSE6784	log	GPL571
GSE6784b	both	MCF-10A (mammary epithelial cell line)	BTO:0001939	EGF treatment after 24 h serum starvation (Control 0 h)	activating	1 h	timeseries with 20, 40, 60, 120, 240, 480 min	GSE6784	log	GPL571
GSE6784c	both	MCF-10A (mammary epithelial cell line)	BTO:0001939	EGF treatment after 24 h serum starvation (Control 0 h)	activating	2 h	timeseries with 20, 40, 60, 120, 240, 480 min	GSE6784	log	GPL571
GSE6784d	both	MCF-10A (mammary epithelial cell line)	BTO:0001939	EGF treatment after 24 h serum starvation (Control 0 h)	activating	4 h	timeseries with 20, 40, 60, 120, 240, 480 min	GSE6784	log	GPL571
GSE7403a	both	SH-SY5Y (Neuroblastoma cells)	BTO:0000793	PDGF treatment with 60 min prior DMSO treatment	activating	0.5 h	timeseries with 30, 60, 120, 240 min	GSE7403	log	GPL96
GSE7403c	both	SH-SY5Y (Neuroblastoma cells)	BTO:0000793	PDGF treatment with 60 min prior DMSO treatment	activating	1 h	timeseries with 30, 60, 120, 240 min	GSE7403	log	GPL96
GSE7403e	both	SH-SY5Y (Neuroblastoma cells)	BTO:0000793	PDGF treatment with 60 min prior DMSO treatment	activating	2 h	timeseries with 30, 60, 120, 240 min	GSE7403	log	GPL96
GSE7403g	both	SH-SY5Y (Neuroblastoma cells)	BTO:0000793	PDGF treatment with 60 min prior DMSO treatment	activating	4 h	timeseries with 30, 60, 120, 240 min	GSE7403	log	GPL96
GSE8471	both	MCF7	BTO:0000093	HRG stimulated (ErbB Ligand)	activating	2 h after stimulation	NA	GSE8471	log	GPL570
GSE12355	notch	EREB2-5 B cell line	BTO:0000739	transfected with Notch1 intracellular domain	activating	8 h	3 replicates each	GSE12355	none	GPL570
GSE29544a	notch	CUTLL1 cells	BTO:0002144	treated with washout of GSI inhibitor	activating	2 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor	GSE29544	none	GPL570
GSE29544b	notch	CUTLL1 cells	BTO:0002144	treated with washout of GSI inhibitor	activating	4 h	3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor	GSE29544	none	GPL570
GSE36176a	notch	A549 cells	BTO:0000018	treated with 2ÂµM GSI RO4929097	inhibiting	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor	GSE36176	none	GPL570
GSE36176b	notch	H460 cells	BTO:0002207	treated with 2ÂµM GSI RO4929097	inhibiting	6 h	4 replicates each, different cell lines, GSI= gamma secretase inhibitor	GSE36176	none	GPL570
GSE12666a	p53	MCF7 cells	BTO:0000093	treated with 10 ÂµM BMH-7, p53 activator	activating	6 h	4 replicates each, lead compounds - mechanism of action unknown	GSE12666	normalized	GPL571
GSE12666b	p53	MCF7 cells	BTO:0000093	treated with 10 ÂµM BMH-9, p53 activator	activating	6 h	4 replicates each, lead compounds - mechanism of action unknown	GSE12666	normalized	GPL571
GSE12666c	p53	MCF7 cells	BTO:0000093	treated with 10 ÂµM BMH-15, p53 activator	activating	6 h	4 replicates each, lead compounds - mechanism of action unknown	GSE12666	normalized	GPL571
GSE12666d	p53	MCF7 cells	BTO:0000093	treated with 10 ÂµM BMH-21, p53 activator	activating	6 h	4 replicates each, lead compounds - mechanism of action unknown	GSE12666	normalized	GPL571
GSE12666e	p53	MCF7 cells	BTO:0000093	treated with 10 ÂµM BMH-22, p53 activator	activating	6 h	4 replicates each, lead compounds - mechanism of action unknown	GSE12666	normalized	GPL571
GSE12666f	p53	MCF7 cells	BTO:0000093	treated with 10 ÂµM BMH-23, p53 activator	activating	6 h	4 replicates each, lead compounds - mechanism of action unknown	GSE12666	normalized	GPL571
GSE13291	p53	MCF7 cells	BTO:0000093	treated with 1 ÂµM RITA, p53 activator	activating	2 h	1 replicate each, RITA inhibits HDM2-p53 interaction	GSE13291	none	GPL571
GSE2238	p53	HT1080 fibrosarcoma cells	BTO:0001282	treated with doxorubicin	activating	6 h	1 replicate each	GSE2238	none	GPL96
GSE23010	p53	U2OS cells	BTO:0001938	treated with 5 GY X-Ray irradiation	activating	4 h	3 replicates each, cells transfected with control sh RNA	GSE23010	normalized	GPL6884
GSE30240a	p53	G361 cells	BTO:0001584	treated with 5 GY X-Ray irradiation	activating	3 h	3 replicates each, part of timeseries, timerespective control, 5 different tissues	GSE30240	none	GPL570
GSE30240b	p53	G361 cells	BTO:0001584	treated with 5 GY X-Ray irradiation	activating	6 h	3 replicates each, part of timeseries, timerespective control, 5 different tissues	GSE30240	none	GPL570
GSE30240c	p53	HepG2 cells	BTO:0000599	treated with 5 GY X-Ray irradiation	activating	3 h	3 replicates each, part of timeseries, timerespective control, 5 different tissues	GSE30240	none	GPL570
GSE30240d	p53	HepG2 cells	BTO:0000599	treated with 5 GY X-Ray irradiation	activating	6 h	3 replicates each, part of timeseries, timerespective control, 5 different tissues	GSE30240	none	GPL570
GSE30240e	p53	TK6 cells	BTO:0003707	treated with 5 GY X-Ray irradiation	activating	3 h	3 replicates each, part of timeseries, timerespective control, 5 different tissues	GSE30240	none	GPL570
GSE30240f	p53	TK6 cells	BTO:0003707	treated with 5 GY X-Ray irradiation	activating	6 h	3 replicates each, part of timeseries, timerespective control, 5 different tissues	GSE30240	none	GPL570
GSE30240g	p53	U2OS cells	BTO:0001938	treated with 5 GY X-Ray irradiation	activating	3 h	3 replicates each, part of timeseries, timerespective control, 5 different tissues	GSE30240	none	GPL570
GSE30240h	p53	U2OS cells	BTO:0001938	treated with 5 GY X-Ray irradiation	activating	6 h	3 replicates each, part of timeseries, timerespective control, 5 different tissues	GSE30240	none	GPL570
GSE30240i	p53	BJ cells	BTO:0003807	treated with 5 GY X-Ray irradiation	activating	3 h	3 replicates each, part of timeseries, timerespective control, 5 different tissues	GSE30240	none	GPL570
GSE30240j	p53	BJ cells	BTO:0003807	treated with 5 GY X-Ray irradiation	activating	6 h	3 replicates each, part of timeseries, timerespective control, 5 different tissues	GSE30240	none	GPL570
GSE32441	p53	HT1080 fibrosarcoma cells	BTO:0001282	treated with 0.25 Âµg/ml doxorubicin	activating	6 h	1 replicate each	GSE32441	none	GPL4133
GSE8939a	p53	CS-B wt rescued cells	BTO:0001489	treated with 10 J/m2 UVC irradiation	activating	2 h	3 replicates each, 2 arrays per sample	GSE8939	none	GPL96
GSE8939b	p53	CS-B wt rescued cells	BTO:0001489	treated with 10 J/m2 UVC irradiation	activating	2 h	3 replicates each, 2 arrays per sample	GSE8939	none	GPL97
